

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 March 2009 (26.03.2009)

PCT

(10) International Publication Number
WO 2009/037454 A2

(51) International Patent Classification:

G01N 33/574 (2006.01)

(21) International Application Number:

PCT/GB2008/003160

(22) International Filing Date:

18 September 2008 (18.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0718167.0 18 September 2007 (18.09.2007) GB

(71) Applicant (for all designated States except US): CANCER RESEARCH TECHNOLOGY LTD [GB/GB]; Sardinia House, Sardinia House, London WC2A 3NL (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): BALKWILL, Frances [GB/GB]; Centre for Translational Oncology Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ (GB).

SLETTENAAR, Violet [NL/GB]; Centre for Translational Oncology Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ (GB). WILSON, Julia [GB/GB]; Centre for Translational Oncology Institute of Cancer, Barts and The London School Of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ (GB). WANG, Yaohe [CN/GB]; Centre for Molecular Oncology Institute of Cancer, Barts and The Londond School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ (GB). SCHIOPPA, Tiziana [IT/GB]; Centre for Molecular Oncology Institute of Cancer, Barts and The Londond School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ (GB).

(74) Agent: WILLIAMS, Richard; HARRISON GODDARD FOOTE, 40-43 Chancery Lane, London WC2A 1JA (GB).

[Continued on next page]

(54) Title: CANCER MARKER AND THERAPEUTIC TARGET



(57) Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

CANCER MARKER AND THERAPEUTIC TARGETFIELD OF THE INVENTION

5 The invention relates to oncology and methods of cancer diagnosis, stratification, disease staging and treatment. The field of the invention therefore concerns markers of predictive or clinical value in cancer diagnosis and treatment and the use of medicaments for the treatment of cancer. The invention also concerns screening assays for identifying active anti-cancer agents.

10

BACKGROUND TO THE INVENTION

Chemokine receptors and their ligands direct the trafficking of cells in normal tissue homeostasis and in disease, influencing cell motility, invasiveness and survival [1].

15 In inflammation and in cancer, chemokines in the diseased tissues contribute to the rolling, tethering and invasion of leucocytes from the blood vessels through the endothelial cell basement membrane and into the parenchyma [2].

20 CCR4 is one of 18 known chemokine receptors. Chemokine receptors are generally expressed on immune cells and in the tumour microenvironment a number of receptors and their ligands are present in the immune cell infiltrate.

25 In many cancers, malignant cells also express certain chemokine receptors, receptors that are not usually found on their normal counterparts. Metastatic cancer cells are thought to gain characteristics of chemokine receptor-expressing leucocytes, using chemokines to aid their migration to, and survival at, sites distant to the original tumour [3, 4, 5]. Inappropriate presence on cancer cells of chemokine receptors that usually have a highly restricted pattern of expression further supports the hypothesis that specific chemokine receptors may help cells spread to, and/or survive in, 30 different metastatic sites [8]. In carcinomas, melanomas and haematological malignancies, expression of chemokine receptors, especially CXCR4 and CCR7, on malignant cells in advanced disease, correlates with increased lymph node metastasis, greater dissemination of disease, lower disease-free survival and/or overall survival [6,7,8]. CXCR5 is normally restricted to B cells and some T cell

subtypes, but is also expressed by pancreatic cancer cells where it is implicated in the establishment of liver metastases; the liver being a site of production of the CXCR5 ligand, CXCL13 [9]. Melanoma cells that have metastasised to the intestine express CCR9 [10]. In homeostasis, the CCR9 ligand CCL25 recruits rare T cell subsets to the intestine. In pancreatic cancer, expression of CCR6 has been observed [38][39]. CCR6 expression has also been reported in human renal carcinoma, together with CCR3 and CXCR2 [40].

This demonstrates that a few chemokine receptors are known to be upregulated in 10 tumour epithelial cells in late stage carcinogenesis, including CXCR4, and are thought to play a role in invasion and metastasis. In contrast, CCR4 has only previously been reported to be upregulated in some blood cancers, particularly T cell lymphomas.

15 As described above, CXCR4 is commonly found on malignant cells in many advanced human cancers. In addition, Woerner *et al* found that CXCR4 was also present in the early stages of disease in glioblastoma [20]. However, using a phospho-specific anti-CXCR4 antibody, they found that in the less malignant Grade 1 lesions, the level of receptor activation was much lower.

20 Although it is generally reported that malignant cell chemokine receptor expression is associated with advanced disease, there are also a few other reports in the art of expression of a chemokine receptor on malignant cells at early and pre-invasive stages of cancer, but all of these concern CXCR4. In a large tissue array study (over 25 2000 samples) of breast cancer, cytoplasmic/membrane expression of CXCR4 expression was reported in 67% of ductal carcinomas *in situ*, DCIS [21]. This was confirmed in a study from Schmid *et al* who showed that both CXCR4 and its ligand CXCL12 were expressed in DCIS [22]. The inventors have also found CXCR4 on the epithelial cells of borderline non-invasive ovarian cancer tumours (Kulbe *et al.*, 30 manuscript in preparation) and this has also been reported by Pils *et al* [23].

No data on expression of other chemokine receptors on epithelial cells in early cancers is available, but there is evidence that oncogenic pathways can induce chemokine receptor expression on epithelial cells. The RET/PTC1 oncogene is

necessary and sufficient for malignant transformation of primary thyrocytes [24]. This oncogene induces a pro-inflammatory programme in the thyrocytes that includes induction of functional CXCR4. Alveolar rhabdomyosarcoma is a highly aggressive tumour characterised by recurrent PAX3 and PAX7-FKHR gene fusions.

5 Transfer of PAX3-FKHR into embryonal rhabdomyosarcoma cells also activates CXCR4 expression [Libura, 2002 #9346].

In all these studies a conclusion is that acquisition of certain chemokine receptors by malignant cells appears to be, a relatively late event in malignant progression, and in
10 the case of CCR4, expression has not been reported at any stage of solid tumour development

CCR4 expression is generally restricted to the immune system, and is known as a marker of Th2 and regulatory T cells. In the tumour environment, these cells act to
15 suppress cytotoxic T cells and dendritic cell maturation, hence suppressing anti-tumour immune responses. In addition, CCR4 has been shown to be expressed in haematological malignancies, including by a high proportion of adult T cell lymphomas (ATL), and was a significant prognostic factor associated with metastasis to skin [35], [41]. As such, CCR4 is of interest as a therapeutic target in ATL [37],
20 [42]. CCR4 expression by adult T cell leukaemia is associated with skin metastases; its ligands CCL17 and CCL22 are produced by both malignant cells and the skin tumor microenvironment [36]. Ishida *et al* have developed an anti-CCR4 monoclonal antibody therapeutic for the treatment of adult T cell lymphoma that induces ADCC activity against the tumor cells and may also act on immunosuppressive malignant
25 Treg cells found in this disease [37].

The only report in the academic literature of a CCR4 positive solid tumor cell line is the human lung cancer cell line SBC-5 [34]. These cells migrated towards CCL22 gradients and in bone metastatic SBC-5 xenografts there was close co-localisation of
30 osteoclasts expressing CCL22 and SBC-5 cells expressing CCR4. There are no reports of CCR4 expression in primary human tumour cells.

WO05106471 (BAYER HEALTHCARE AG) discloses screening methods for agents of potential use in treating a wide range of diseases; specifically consisting of

cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, haematological disorders, cancer disorders, neurological disorders, respiratory diseases and reproduction disorders in a mammal. The screening method determines the degree of binding or otherwise of candidate agents to CCR4. There is also a description of the screening of a wide range of human cells and tissues for their expression level of CCR4 relative to housekeeping gene expression. The cells and tissues were obtained from disparate sources and just an isolated few were cancerous cells/tissues; e.g. thyroid, ileum, HeLa, Jurkat, lung and breast cancer cells. The results for the relative expression of CCR4 show no distinguishable pattern associated with any particular disease. Indeed amongst tumour cells tested, e.g. thyroid and ileum, there were low levels of relative expression of CCR4 and other non-tumour cells showed higher levels of relative expression of CCR4.

WO9623068 (GLAXO GROUP LIMITED) discloses a chemokine receptor able to bind to Monocyte Chemotactic Protein-1 (MCP-1 / CCL2), Macrophage Inflammatory Protein 1 α (MIP1 α / CCL3) and/or 'RANTES' (Regulated upon Activation, Normal T-cell Expressed, and Secreted / CCL5). A nucleotide and an amino-acid sequence for CCR4 are disclosed (CC-CKR-4 / K5.5. K5.5 and CC-CKR-4 are alternative names for CCR4.) The expression of CCR4 is discovered in a relatively limited range of normal human tissues and in a range of T-cell samples. There is also general disclosure of screening assays for agents capable of activating T-lymphocytes or blocking binding of ligands MCP-1, MIP-1 α and/or RANTES to the chemokine receptor. There is some suggestion that active agents obtained via screening may be useful in the treatment of allergies, for example.

WO0041724A1 (LELAND STANFORD / LEUKOSITE) proposes the modulation of systemic memory T cell trafficking by administration of CCR4 modulating agents. This is intended as a treatment for inflammatory skin disease. Substances capable of modulating CCR4 binding to its ligands are used in *in vitro* tests to show how T-cell migration is affected.

Antibodies reactive against CCR4 are known. WO0164754 (Kyowa Hakko Kogyo) discloses a recombinant antibody or fragment thereof allegedly reactive specifically with the extracellular domain of CCR4. Also disclosed is a polypeptide sequence of such an antibody. There is also disclosed an antibody which reacts with a CCR4

5 positive cell and is cytotoxic or causes antibody-dependent cell-mediated cytotoxicity (ADCC.) These antibodies are proposed for the use in the treatment of Th2-mediated immune diseases or blood cancer, specifically leukaemia.

10 WO05035582 (Kyowa Hakko Kogyo) discloses an antibody capable of specifically binding CCR4 and also discloses a CCR4 antibody which has a complex N-linked glycosylation in the Fc region. Also disclosed are antibodies to the extracellular domains of CCR4.

15 WO03018635 (Kyowa Hakko Kogyo) discloses 'Human CDR-grafted antibodies and fragments'. A specific CDR (complementarity determining region) which binds specifically to CCR4 is disclosed. The antibodies are proposed for use in the diagnosis or treatment of Th2-mediated immune diseases or cancers such as blood cancers.

20 WO05053741 (Kyowa Hakko Kogyo) discloses a medicament comprising a recombinant antibody, which specifically binds CCR4, in combination with at least one other agent. The antibody is proposed for the treatment of tumours, specifically haematopoietic organ tumours.

25 WO0042074 (MILLENIUM PHARMACEUTICALS) discloses antibodies to CCR4 and antibodies that can compete with their binding. No specific diagnostic applications are disclosed. Therapy of inflammatory disorders is proposed.

30 Also known in the art are a variety of small molecules that bind to the CCR4 receptor.

WO04007472 (ONO PHARMACEUTICAL CO.) discloses a small molecule tricyclic compound with anti-CCR4 activity.

WO05023771 (ONO PHARMACEUTICAL CO.) discloses small molecule nitrogen-containing heterocyclic compounds with anti-CCR4 activity.

5 WO02094264 (TULARIK INC.) discloses specific compounds with CCR4 inhibitory activities.

WO0230358 (TULARIK / CHEMOCENTRYX) discloses various CCR4-binding compounds and uses for treatment of various diseases, but not including cancer.

10 10 WO0230357 (CHEMOCENTRYX) discloses compounds that are antagonists of CCR4. This application describes uses for the treatment of inflammatory diseases and conditions.

15 WO051236976 (ASTELLAS PHARMA INC.) discloses quinazoline derivatives as CCR4 regulators.

WO05085212 (YAMANOUCHI PHARMACEUTICAL CO., LTD.) discloses pyrimidine derivatives as CCR4 modulators.

20 20 WO05082865 (YAMANOUCHI PHARMACEUTICAL CO., LTD.) discloses fused bicyclic pyrimidine derivatives as CCR4 function-controlling agents.

WO04108717 (ASTRAZENECA AB) discloses sulphonamide compounds that modulate chemokine (specifically CCR4) receptor activity.

25 25 EP1633729 (ASTRAZENECA AB) discloses sulphonamide compounds that modulate chemokine (specifically CCR4) receptor activity.

30 WO03014153 (TOPIGEN PHARMACEUTIQUE INC.) discloses another technology in the art, a method of modulating viral infection of a cell by modulating the interaction between chemokine receptors (including CCR4) and a virus.

WO2004/045526 (Morehouse School of Medicine) discloses antibodies to particular chemokines and chemokine receptors and their use in inhibiting the growth and

metastasis of cancer cells. Antibodies were raised against the particular chemokine receptors and their ligands, which does not include CCR4. Also described are methods of testing for over-expression of particular chemokines in a tumour and the suggestion that such tumours can be treated by administering antibodies against the 5 particular over-expressed chemokine or chemokine receptor.

WO99/15666 (Icos Corporation) discloses nucleotide sequences and polypeptide sequences of a macrophage-derived C-C chemokine designated 'Macrophage Derived Chemokine' (MDC). MDC appears synonymous with CCL22. TARC 10 appears synonymous with CCL17. Methods for the recombinant or synthetic production of MDC protein or polypeptide fragments are described. Also disclosed are antibodies reactive with MDC as well as assays for identifying modulators of MDC and TARC chemokine activity.

15 Cervical cancer is the second most common type of cancer in women worldwide. Symptoms are often absent until the cancer is at a late stage and hence cervical cancer has been the subject of an intense population screening program using the Pap smear, which can detect pre-malignant changes by histopathology. Although an abnormal Pap smear indicates possible cervical neoplasia, it is insufficient for 20 diagnosis, which is subsequently carried out by biopsy and additional invasive procedures ('colposcopy'). In total, 24,000 women are referred in the UK each year with abnormal Pap smears. The Pap smear has only 70% sensitivity, hence a significant proportion of women with cervical cancer or pre-invasive lesions remain 25 undiagnosed. Therefore, more accurate screening methods are required to i) allow screening to be more automated and less subjective ii) to improve the sensitivity of screening.

HPV (Human Papilloma Virus) infection is found in the majority of invasive cervical carcinomas, one strategy is to screen for the presence of HPV markers such as E6 30 and E7 in concert with the Pap smear. However, due to the high level of HPV infection in the sexually active population (up to 80% infection history), this also results in the identification of a large number of false positives and makes the accuracy of the test dependent on HPV prevalence. As such, identifying new biomarkers for cervical cancer remains an area of active interest.

Furthermore new or alternative biomarkers are required for other forms of cancer including, but not limited to, the following cancer types: bronchial, nasopharyngeal, laryngeal, small cell and non-small cell lung, skin (e.g. melanoma or basal cell

5 carcinoma), brain, pancreatic, neck, lung, kidney, liver, breast, colon, bladder, oesophagus, stomach, cervical, ovarian, germ cell and prostate. A biomarker characteristic of one cancer type may be shared with other cancer types thus the use of a biomarker may extend beyond the original cancer type it was found to be associated with.

10

There is a need for improved biomarkers for a range of cancers which allow for stratification of patients in need of anti-cancer treatment.

15 The stage of a cancer is a descriptor (usually numbers I to IV) of how much the cancer has spread. The stage often takes into account the size of a tumour, how deep it has penetrated, whether it has invaded adjacent organs, if and how many lymph nodes it has metastasized to, and whether it has spread to distant organs. Staging of cancer is important because the stage at diagnosis is the most powerful predictor of survival, and treatments are often changed based on the stage

20

Correct staging is critical because treatment is directly related to disease stage. Thus, incorrect staging would lead to improper treatment, and material diminution of patient survivability. Correct staging, however, can be difficult to achieve.

25 Pathologic staging, where a pathologist examines sections of tissue, can be particularly problematic for two specific reasons: visual discretion and random sampling of tissue. "Visual discretion" means being able to identify single cancerous cells intermixed with healthy cells on a slide. Oversight of one cell can mean misstaging and lead to serious, unexpected spread of cancer. "Random sampling" refers to the fact that samples are chosen at random from patients' lymph nodes and are examined. If cancerous cells present in the lymph node happen not to be present in the slices of tissue viewed, incorrect staging and improper treatment can result.

30 There is an ongoing need for new treatments against cancer, whether these involve improved ways of administering existing anti-cancer agents, or whether these involve

identifying, testing and verifying effective new anti-cancer agents. There is also an ongoing need for improved methods of monitoring the efficacy of existing and any new anti-cancer agents in the course of a given treatment regime. Improved methods of generating data of predictive value are needed. The dosage and frequency of treatments using anti-cancer agents is an important factor. Also, the timing of the start of an anti-cancer treatment relative to the stage of progression of a cancer, or relative to a patient group, are important factors. Improved methods of monitoring are required in order to seek optimal treatments for patients, whether as individuals or classified into groups by virtue of genetic, phenotypic or other characteristics.

10

An example of the prognostic function of a biomarker in the choice of treatment for a patient is the use of the anti-cancer drug Herceptin (Trastumuzab). The HER2/neu gene is a proto-oncogene located at the long arm of human chromosome 17(17q11.2-q12) and amplification of HER2/neu occurs in 25-30% of early-stage breast cancers.

15

In cancer the growth promoting signals from HER2/neu are constitutively transmitted, promoting invasion, survival and angiogenesis of cells. Furthermore overexpression can also confer therapeutic resistance to cancer therapies. Herceptin (Trastumuzab) is a humanised monoclonal antibody which binds to the extracellular segment of the receptor HER2/neu, (also known as ErbB-2) and is only effective in treating breast cancer where the HER2/neu receptor is overexpressed. Because of its prognostic role as well as its ability to predict a patient's response to Herceptin breast tumors are routinely checked for overexpression of HER2/neu by a variety of techniques including immunohistochemistry (IHC) Chromogenic and fluorescence in situ hybridisation (CISH and FISH respectively).

25

There also exists the need for more accurate and reliable methods of diagnosing / staging of cancers and a need for new methods for screening anti-cancer agents.

SUMMARY OF THE INVENTION

30

The inventors have surprisingly discovered that in certain solid tumours, chemokine receptor CCR4 expression is an early event in carcinogenesis. In addition the inventors have discovered that the expression of two ligands of CCR4, CCL17 and CCL22, increases during tumour progression.

The present invention provides a method of obtaining information of predictive or diagnostic character for a cancer patient, comprising the step of measuring the amount and/or activity of chemokine receptor CCR4 expressed by tumour cells in a 5 solid tumour sample or in a non-haematological cell tumour sample taken from the patient, the amount and/or activity of CCR4 providing the information of predictive or diagnostic character.

Haematological tumours are derived from blood cells, including immune cells and 10 include leukaemias and lymphomas of various types. The invention does not therefore concern haematological tumours.

In the solid or non-haematological tumours which the invention is concerned with, CCR4 is expressed by cells of the tumour. The methods of the invention therefore 15 concern the CCR4 expressed by samples of patient tumour cells (or reference cells) and substantially not by cells of the immune system. To the extent that CCR4 arises in any patient tumour samples from an undesired source, such as infiltrating immune cells, the amount and/or activity of CCR4 being measured in accordance with the invention is either not significant or it is controlled for in any measurements being 20 made.

In preferred embodiments, the reference amount and/or level of activity of CCR4 may be measured in one or more non-tumour samples. The, or at least one non-tumour sample may be taken from the patient. When a reference amount and/or level 25 of activity of CCR4 is determined from non-tumour cells of the patient, a single sample of non-tumour tissue may be taken from the patient. If desired, a multiplicity of non-tumour samples can be taken from different locations of the same patient. The reference amount may therefore be a mean figure determined from a number of samples taken from the patient.

30 In other embodiments, the one or more non-tumour samples are optionally not taken from the patient. Such samples may be taken from other patients and may include cultured tumour cell lines.

The information may be used to predict whether the solid tumour or the non-haematological cell tumour of the patient will be susceptible to an anti-cancer treatment. This aspect of the invention advantageously permits stratification of cancer patients. This allows an optimal anti-cancer treatment or regime to be

5 identified for a given individual patient.

In preferred embodiments, the patient will have received an anti-cancer treatment and measurements of the amount and/or activity of CCR4 in the solid tumour sample or the non-haematological tumour sample of the patient may be made before and after

10 the start of treatment, and the information obtained is then used to determine whether the solid tumour or the non-haematological cell tumour of the patient has responded to the anti-cancer treatment. This aspect of the invention advantageously permits monitoring of cancer patients to determine how their individual treatment is

15 progressing. Adjustments to the treatment regime may be made in light of the progress being made.

The information may be used in diagnosis of a solid tumour or a non-haematological cell tumour.

20 The information may be used to stage a solid tumour or a non-haematological cell tumour.

The invention also provides a method of obtaining information of predictive or diagnostic character for a cancer patient whose tumour cells express chemokine

25 receptor CCR4, comprising the step of measuring the amount and/or activity of CCR4 ligand CCL17 and/or CCL22 in a solid tumour sample or in a non-haematological cell tumour sample taken from the patient, the amount and/or activity of CCL17 and/or CCL22 providing the information of predictive or diagnostic character.

30 The information of predictive or diagnostic character may be obtained by comparing the amount and/or activity of CCL17 and/or CCL22 in the solid tumour sample or in the non-haematological cell tumour sample with a reference amount and/or level of activity of CCL17 and/or CCL22.

The reference amount and/or level of activity of CCL17 and/or CCL22 may be measured in one or more non-tumour samples. As in the previous aspect of the invention, non-tumour samples may be taken from the patient or from a different patient or source, including cultured cell lines.

5 The information may be used to predict whether the solid tumour or the non-haematological cell tumour of the patient will be susceptible to an anti-cancer treatment.

10

In further optional embodiments, the patient has received an anti-cancer treatment and measurements of the amount and/or activity of CCL17 and or CCL22 are made before and after the start of treatment and the information obtained is used to determine whether the solid tumour or the non-haematological cell tumour of the patient has responded to the anti-cancer treatment.

15

In all aspects of the invention, a particular anti-cancer treatment may comprise an agent which modulates or inhibits CCR4 expression or activity.

20

The invention also provides the use of an antibody reactive against chemokine receptor CCR4 for detecting the presence or measuring the amount of CCR4 expressed by a solid tumour or a non-haematological tumour in a cancer patient, the presence or amount of CCR4 expressed by the tumour and when detected or measured providing the information of diagnostic character.

25

The invention further provides the use of an oligonucleotide primer or probe capable of hybridizing under stringent conditions to a nucleic acid of SEQ ID NO:1 for detecting or measuring the amount of expression of CCR4 by cells of a solid tumour or a non-haematological tumour, the presence or amount of CCR4 expressed by the tumour when detected or measured providing the information of diagnostic character.

30

The aforementioned uses to which the information may be put are as hereinbefore defined in relation to the method aspects of the invention.

The nucleic acid of SEQ ID NO:1 is not limited to the specific sequence, but includes variants which still encode biologically active CCR4 protein. Such variants may include nucleotide sequences having at least 99% identity with SEQ ID NO:1. Other variants may have at least 95%, optionally at least 90% identity. The range of 5 identities of from at least 65% to at least 99% identity with SEQ ID NO:1 is disclosed herein.

A variety of stringent hybridisation conditions will be familiar to the skilled reader in the field. Hybridization of a nucleic acid molecule occurs when two complementary 10 nucleic acid molecules undergo an amount of hydrogen bonding to each other. The stringency of hybridization can vary according to the environmental conditions surrounding the nucleic acids, the nature of the hybridization method, and the composition and length of the nucleic acid molecules used. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are 15 discussed in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001); and Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes Part I, Chapter 2 (Elsevier, New York, 1993). The T_m is the 20 temperature at which 50% of a given strand of a nucleic acid molecule is hybridized to its complementary strand. The following is an exemplary set of hybridization conditions and is not limiting:

Very High Stringency (allows sequences that share at least 90% identity to hybridize)

25 Hybridization: 5x SSC at 65°C for 16 hours
 Wash twice: 2x SSC at room temperature (RT) for 15 minutes each
 Wash twice: 0.5x SSC at 65°C for 20 minutes each

High Stringency (allows sequences that share at least 80% identity to hybridize)

30 Hybridization: 5x-6x SSC at 65°C-70°C for 16-20 hours
 Wash twice: 2x SSC at RT for 5-20 minutes each
 Wash twice: 1x SSC at 55°C-70°C for 30 minutes each

Low Stringency (allows sequences that share at least 50% identity to hybridize)

Hybridization: 6x SSC at RT to 55°C for 16-20 hours

Wash at least twice: 2x-3x SSC at RT to 55°C for 20-30 minutes each.

5 The invention includes a method of treating a cancer patient having a solid tumour or a non-haematological tumour expressing CCR4, comprising administering an effective amount of an agent which modulates or inhibits CCR4 expression or activity.

10 The agent may be administered in the form of a pharmaceutical formulation. Suitable formulations include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The compositions may further comprise auxiliary agents or excipients, as known in the art, see, e.g., Berkow et al., The Merck Manual, 16th edition Merck & Co., Rahm, NJ (1992), Avery's Drug Treatment: Principles and

15 Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, Ltd., Williams and Wilkins, Baltimore, MD (1987) & Osol (ed.), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 1324-1341 (1980). The pharmaceutical compositions administered in accordance with the invention are preferably presented in the form of individual doses (unit doses).

20 A composition or medicament employed in the methods and uses of the invention may further comprise salts, buffers, or other substances which are desirable for improving the efficacy of the composition. The administration of composition or medicament in accordance with the invention may be local or systemic.

25 The invention also includes the use of a chemokine receptor CCR4 modulating or inhibiting agent for the treatment or prevention of solid tumours or non-haematological tumours.

30 In all of the aforementioned method and use aspects of the invention, the agent which modulates or inhibits CCR4 expression or activity may be:

(i) an antibody which binds to CCR4; optionally an anti-CCR4 antibody as disclosed in any of WO0041724, WO0164754, WO05035582, WO03018635, WO05053741, WO0042074; or

5 (ii) an antibody which binds to CCR4 ligands CCL17 or CCL22; optionally anti-CCL17 or anti-CCL22 antibodies as disclosed in WO99/15666 or Ishida, T., *et al* (2004) *Clin Cancer Res* 10:7529-7539.

10 (iii) a CCR4 antagonist; optionally a CCR4 antagonist as disclosed in any of WO04007472, WO05023771, WO02094264, WO0230358, WO0230357, WO051236976, WO05085212, WO05082865, WO04108717, EP1633729, WO03014153.

15 Appropriate compositions and formulations of active agents include those described in the aforementioned publications.

The invention further provides a kit for obtaining information of predictive or diagnostic character for a cancer patient from a solid tumour or a non-haematological tumour sample from the patient, wherein the kit comprises:

20 at least one reagent selected from an antibody reactive with CCR4, an antibody reactive with CCL17, an antibody reactive with CCL22, and an oligonucleotide probe or primer capable of hybridizing with SEQ ID NO:1 under stringent conditions; and

25 indicia directing a user of the kit to apply the reagent to a sample of a solid tumour or a non-haematological tumour from a patient so as to measure the amount and/or activity of one or more of CCR4, CCL17 and CCL22 in the sample.

30 In certain embodiments, the kit may comprise a reference sample of one or more non-tumour cells and the indicia are a set of instructions and direct the user of the kit to measure the amount and/or level of activity of one or more of CCR4, CCL17 and CCL22 in both the patient sample and the reference sample. The reference sample(s)

may comprise cultured tumour cell or cell extracts.

In other embodiments, the indicia may be a set of instructions and include reference values for the reference amount and/or level of activity of one or more of CCR4,

5 CCL17 and CCL22. The reference values are preferably obtained by previous work carried out by making measurements of amounts and/or activity of CCR4, CCL17 or CCL22 in selected non-tumour samples from individuals or patients, whether or not they have or have had a cancerous condition. Such previous measurements may have been carried out on cultured non-tumour human cell lines.

10

The invention also includes a method of screening for an anti-cancer agent active against a solid tumour or a non-hematological tumour which expresses chemokine receptor CCR4 comprising the steps of:

- i) providing test cells that express CCR4 and are capable of, or are in the process of exhibiting a biological activity selected from (a) proliferation, (b) migration, (c) secretion of a protein or a signalling molecule, or (d) cell survival when cultured under specified conditions;
- ii) exposing the test cells to a candidate agent for a period of time,
- iii) measuring the biological activity of the test cells, whereby no biological activity or biological activity which is less than the expected activity of such test cells in the absence of candidate agent identifies an anti-cancer agent.

20

In preferred methods, a control aliquot of test cells is not exposed to the candidate agent and the biological activity of the control cells is measured so that the expected biological activity is determined.

25

The biological activity of the test cells and any control cells may be induced by the addition of a ligand of the CCR4 receptor, preferably CCL17 and/or CCL22.

30

In all aspects of the invention, the solid tumour or non-haematological tumour may be a cancer selected from cancer of the cervix, oesophagus, kidney, brain, breast, ovary, prostate, stomach or pancreas. The invention may be of particular advantage in relation to cancers of the cervix, oesophagus, kidney, brain, breast and ovary.

The invention therefore provides a method for determining whether a cancer patient is suitable for treatment with an agent that modulates CCR4 expression and/or CCR4 activity, comprising determining the amount or activity of CCR4 in a sample of 5 patient tumour cells.

The invention further provides a method for determining whether a cancer patient is suitable for treatment with an agent that modulates the levels or activity of CCL17 and/or CCL22, comprising determining the amount or activity of CCL17 and/or 10 CCL22 in a sample of patient tumour cells.

The invention therefore provides for the use CCR4, CCL17, and/or CCL22 as a biomarker for stratification of cancer patients according to their suitability for treatment with CCR4, CCL17 and/or CCL22 modulating or inhibiting agents, 15 including the agents disclosed herein.

The suitability of a cancer patient for treatment with a particular therapeutic agent is governed by a multiplicity of factors, some inter-related. Patient age, sex, stage of the cancer, type of cancer, genetic make up of patient, lifestyle factors, such as diet or 20 smoking, may all impact on the potential outcome of a given treatment regime.

Stratification is usually undertaken in order to group patients on the basis of a multiplicity of selected parameters that can allow predictions to be made in terms of clinical outcome for a group of patients or an individual patient falling within a group.

25

Generally, an increased level or activity of one or more of CCR4, CCL17 and/or CCL22 in a patient tumour sample is indicative of a patient for whom treatment with the anti-cancer agents disclosed herein is beneficial.

30 The invention also includes a method of monitoring the efficiency of an anti-cancer treatment in a patient comprising determining the amount or activity of CCR4 in a sample of tumour cells from the patient,

The invention further includes a method of monitoring the efficiency of an anti-cancer treatment in a patient comprising determining the amount or activity of CCL17 and/or CCL22 in a sample of tumour cells from the patient.

5 In the aforementioned methods, the sampling of tumour cells may take place before, during and/or subsequent to the anti-cancer agent being administered.

The invention also provides methods for prevention or treatment of certain solid tumours as described herein comprising administration of an agent selected from:

10 (a) CCR4 modulating agents e.g. as disclosed in WO0041724A1 (LELAND STANFORD / LEUKOSITE);

(b) anti-CCR4 antibodies, e.g. as disclosed in WO0164754 (Kyowa Hakko Kogyo), WO05035582 (Kyowa Hakko Kogyo), WO03018635 (Kyowa Hakko Kogyo), WO05053741 (Kyowa Hakko Kogyo) or

15 WO0042074 (MILLENIUM PHARMACEUTICALS); or

(c) CCR4 antagonists, e.g. as disclosed in WO04007472 (ONO PHARMACEUTICAL CO.), WO05023771 (ONO PHARMACEUTICAL CO.), WO02094264 (TULARIK INC.), WO0230358 (TULARIK / CHEMOCENTRYX), WO0230357 (CHEMOCENTRYX), WO051236976 (ASTELLAS PHARMA INC.), WO05085212 (YAMANOUCHI PHARMACEUTICAL CO., LTD.), WO05082865 (YAMANOUCHI PHARMACEUTICAL CO., LTD.), WO04108717 (ASTRAZENECA AB), EP1633729 (ASTRAZENECA AB) or WO03014153 (TOPIGEN

20 25 PHARMACEUTIQUE INC.)

The invention therefore also provides a method for diagnosing a solid tumour in an individual susceptible to treatment with CCR4 modulating agents, anti-CCR4 antibodies or CCR4 antagonists, comprising determining the level of activity and/or expression of CCR4, CCL17 and/or CCL22 in a tumour sample from the patient.

30 Increased levels of activity and/or expression, whether in absolute terms on a standardized basis having regard to reference values, or whether on a relative (standardized) basis as between (a) tumour/non-tumour cells or (b) tumour cells over

time, is generally indicative of a tumour susceptible to treatment with the anti-CCR4 agents disclosed herein.

The invention includes a method of providing information of diagnostic relevance to
5 the diagnosis or treatment of solid tumours, wherein the method comprises
determining the amount or activity of CCR4, CCL17 and/or CCL22 in a sample of
cells from a patient suspected of having cancer.

The present invention also provides a method of identifying or staging a cancer in an
10 individual comprising determining the level of one or more of the chemokine receptor CCR4, or its ligands CCL22 or CCL17, in a sample of tumour cells obtained from the individual, wherein the cancer is a solid tumour.

Advantageously, the methods of the invention provide a more reliable and more
15 accurate way of identifying, or staging cancer in an individual, or for stratifying individuals for selection of appropriate treatments, particularly in relation to solid tumours, more particularly cervical and oesophageal cancers, but also including cancers selected from the group consisting of bronchial, nasopharyngeal, laryngeal, small cell and non-small cell lung, skin (e.g. melanoma or basal cell carcinoma),
20 brain, pancreatic, neck, lung, kidney, liver, breast, colon, bladder, oesophagus, stomach, cervical, ovarian, germ cell and prostate.

Samples obtained from patients are preferably biopsy samples. A biopsy is a
medical test involving the removal of cells or tissues for examination. The tissue is
25 generally examined under a microscope by a pathologist and/or may be analyzed chemically using techniques well known in the art to assess protein or RNA levels. When a smaller sample of tissue is removed, the procedure is called an incisional biopsy or core biopsy. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. When a sample of tissue or fluid is
30 removed with a needle, the procedure is called a needle aspiration biopsy.

In alternative embodiments samples may be obtained from patients by other methods well known in the art, including but not limited to, samples of blood, serum, urine, sputum, ascites, intraperitoneal fluids and samples of cells taken by a 'smear' test.

5 Blood samples may be taken via venipuncture, (e.g. by vacuum collection tube or syringe,) catheter, cannula, or by finger prick or heel prick as appropriate to the needs of the patient and the amount of blood required. Once a blood sample has been taken it may be treated prior to analysis (e.g. with sodium citrate, EDTA, ethanol or Heparin) for the purposes of preservation or in order to maximise the accuracy and/or reliability of the signal obtained by analysis of the sample.

10 Methods of processing (e.g. centrifugation and/or filtration) may be used to separate a blood sample into fractions each of which may be tested independently. For example, a blood serum sample is produced by allowing a whole-blood sample to clot on contact with air where the clotted fraction is removed by centrifugation to leave the serum as the supernatant.

15 Urine samples are preferably collected by urination or catheterisation.

20 Sputum samples may be collected from the patient by coughing and/or expectoration, or by extracting a sample with a suction tube or needle inserted in the airway. Preferably sputum samples should have minimal contact with saliva to avoid contamination.

25 A smear test (for example a Papancolaou test, also called a Pap smear or cervical smear test) may be used to sample cells from a patient. In the case of a cervical smear test cells are collected and removed from the surface of the tissue being tested by means of physical contact with an Aylesbury spatula, plastic fronded 'broom' or other instrument.

30 The cells and/or liquid collected in a sample taken from a patient may be processed immediately or preserved in a suitable storage medium for later processing. For example, in the case of a cervical smear test the cells are often preserved in an ethanol based storage medium for later processing and analysis. The sample may be treated for the purposes of preservation or for maximising the accuracy and/or reliability of the signal obtained by analysis of the sample. Methods of processing

(e.g. centrifugation and/or filtration) may be used to separate a sample into fractions each of which may be tested independently.

In all of the methods and uses of the invention whether hereinbefore or hereinafter 5 defined or described, the cancers are those that give rise to solid humours. The cancer is also preferably one selected from the group consisting of bronchial, nasopharyngeal, laryngeal, small cell and non-small cell lung, skin (e.g. melanoma or basal cell carcinoma), brain, pancreatic, neck, lung, kidney, liver, breast, colon, bladder, oesophagus, stomach, cervical, ovarian, germ cell and prostate. More 10 preferably the cancers are cancers of the cervix, oesophagus, kidney, brain, breast and ovary.

In other embodiments the cancer may be a carcinoma, preferably a squamous cell carcinoma (SCC) or adenocarcinoma, preferably selected from cancers of the cervix, 15 oesophagus, kidney, brain, breast and ovary.

In preferred embodiments, an increased level of CCR4 and/or CCL17 and/or CCL22 produced by the tumour cells identifies a malignant cancer or a prospectively malignant cancer.

20 The level of one or more of CCR4 and/or CCL17 and/or CCL22 produced in non-tumour cells may be determined and the level in tumour and non-tumour cells compared.

25 In preferred embodiments the level of CCR4 alone is determined. In other embodiments the level of CCL17 or CCL22 alone is determined.

The level of CCR4 and/or CCL17 and/or CCL22 in tumour cells may be compared 30 with pre-determined levels. Pre-determined levels may be derived from normal non-cancerous tissue, earlier stage cancerous tissue, data obtained from databases or directly from available biological material or samples.

Various ways of determining the level of CCR4 and/or CCL17 and/or CCL22 may be employed in methods of the invention. Preferably the protein level and/or activity

of CCR4 and/or CCL17 and/or CCL22 may be used as a measure of the gene products of CCR4 and/or CCL17 and/or CCL22 in the sample.

In a further preferred embodiment, the protein level of CCR4 and/or CCL17 and/or CCL22 is measured using an antibody reactive against CCR4, CCL17 and CCL22 respectively, preferably a specific antibody, e.g. a monoclonal antibody.

The location and amount of specific proteins can be detected by microscopy and histological techniques. Using sample preparation, staining and probing techniques well known in the art, the structure of cells can be shown and specific proteins associated with them can be detected and their location within the sample found.

Histochemical stains are well known in the art and may be used to show cell morphology and/or more specific cellular components. Commonly used stains include hematoxylin (which stains nucleic acids and ergastoplasm, blue) and eosin (which stains elastic and reticular fibres, pink)

Immunohistochemistry is a technique whereby antibodies to specific proteins are used for detection of said proteins in samples. Their binding of antibody to antigen in the sample can be detected in a number of ways.

The most standard method is to conjugate an enzyme that catalyses a colour changing reaction (e.g. alkaline phosphatase, horseradish peroxidase) to the antibody, thus the use of a suitable chromogenic substrate allows visualisation of the location of the antigen under the light microscope. A variation upon this method is immunofluorescence whereby the antibody is conjugated to a fluorophore (e.g. FITC, rhodamine, Texas Red) that emits a detectable signal when excited by a suitable source of energy. Normally this is light of a specific wavelength.

Immunofluorescence is advantageous because the use of multiple fluorophores attached to different antibodies allows detection of multiple targets within a sample and is particularly suitable for confocal laser scanning microscopy, which is highly sensitive and can also be used to visualise interactions between multiple proteins.

Often detection of the specific antigen is done by a, multiply staged, indirect method. An unlabelled or unconjugated 'primary' antibody, raised against the antigen being tested for is used to bind said antigen. This 'primary' antibody may then be detected by a 'secondary' antibody conjugated to a detectable marker and raised such that it 5 will react with the immunoglobulin of the species that the 'primary' antibody was raised in.

Measurement of protein levels using antibodies may use techniques such as ELISA (Enzyme-linked Immunosorbent Assay), RIA (Radioimmunoassay), EMIT (Enzyme 10 Multiplied Immunoassay Technique), protein microarray analysis, flow cytometry, western blotting, dot blotting or slot blotting, preferably the methodology is quantitative.

Flow cytometry is a technique for counting, examining, and sorting microscopic 15 particles suspended in a stream of fluid. It allows simultaneous multiparametric analysis of the physical and/or chemical characteristics of single cells flowing through an optical and/or electronic detection apparatus.

Fluorescence-activated cell-sorting (FACS) is a specialised type of flow cytometry. It 20 provides a method for sorting a heterogeneous mixture of biological cells into two or more containers, one cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. It is a useful scientific instrument as it provides fast, objective and quantitative recording of fluorescent signals from individual cells as well as physical separation of cells of particular interest.

25 The population of cells in a sample is normally heterogeneous. In order to detect the differences between cells, they are treated with chemical and immunochemical techniques similar to those of histochemistry. Immunochemical detection of antigens may be done using antibodies labeled with fluorophores such as FITC, Cy5 and GFP. 30 Staining the cells with dyes (such the DNA binding dyes SYBR-Green and DAPI) may be used to detect differences such as cell size or cell cycle stage within and between samples. Using these techniques in combination allows different cells within the heterogeneous to be given specific fluorescence profiles that are distinguishable by the flow cytometer. In this way cells expressing particular

antigens or associated with particular light scattering profiles may be detected and their prevalence, within the sample population, measured.

Alternatively, the level of CCR4 and/or CCL17 and/or CCL22 may be determined by

5 measuring the level of mRNA encoding CCR4 and/or CCL17 and/or CCL22 as a measure of the level of the gene products of CCR4 and/or CCL17 and/or CCL22 in the sample

In further preferred embodiments of the invention the mRNA level is measured by a

10 quantitative polymerase chain reaction (qPCR) method, preferably a qPCR method where the template is the product of a reverse transcriptase reaction (RT-qPCR.)

In preferred embodiments mRNA is extracted from the sample and reverse transcribed to produce cDNA prior to qPCR.

15

In other preferred embodiments the level of transcription of CCR4 and/or CCL17 and/or CCL22 is measured using a nuclease protection assay, preferably the probe used is specific for CCR4 and/or CCL17 and/or CCL22.

20 In other preferred embodiments of the invention the mRNA level is measured using a DNA microarray.

A DNA microarray (also known as gene or genome chip, DNA chip, or gene array) is a collection of microscopic DNA spots, commonly representing single genes,

25 arrayed on a solid surface by covalent attachment to chemically suitable matrices.

Qualitative or quantitative measurements with DNA microarrays utilize the selective nature of DNA-DNA or DNA-RNA hybridization under high-stringency conditions. Fluorophore-based detection may be used to determine the degree of hybridisation from which a quantitative measurement may be calculated.

30

In preferred embodiments, the cancer is a malignant cancer. Alternatively, the cancer may be a pre-malignant cancer. The method of the invention can advantageously identify the stage to which cancer in a patient has progressed, thereby permitting identification of the most appropriate course of treatment.

Consistent with the method of the invention herein before described, including all subsidiary aspects, the invention also provides for the use of CCR4 receptor as a marker for the identification and/or staging of cancer. The CCR4 receptor may be 5 detected by means of an antibody, preferably a specific antibody, e.g. a monoclonal antibody.

Similarly, the invention also provides for the use of CCL17 ligand as a marker for the identification and/or staging of cancer. The CCL17 ligand may be detected by 10 means of an antibody, preferably a specific antibody, e.g. a monoclonal antibody.

The invention also provides for the use of CCL22 ligand as a marker for the identification and/or staging of cancer. The CCL22 ligand may be detected by means of an antibody, preferably a specific antibody, e.g. a monoclonal antibody.

15 The invention includes a method of treating or preventing malignant disease in an individual suffering from cancer comprising treating the individual with an effective amount of antibodies reactive against reactive against CCR4 and/or CCL17 and/or CCL22. The invention therefore provides the use of antibodies reactive against 20 CCR4 and/or CCL17 and/or CCL22 for the manufacture of a medicament for the treatment or prevention of cancer in an individual suffering from cancer.

25 In a further embodiment of the invention antibodies reactive against CCR4 and/or CCL17 and/or CCL22 may be used in the manufacture of a medicament for the treatment or prevention of cancer.

In a preferred embodiment, the medicament comprises an antibody specific for CCR4, and may be a monoclonal antibody.

30 Embodiments of this aspect of the invention are, for example, the antibodies disclosed in WO0164754 (Kyowa Hakko Kogyo), WO05035582 (Kyowa Hakko Kogyo), WO03018635 (Kyowa Hakko Kogyo), WO05053741 (Kyowa Hakko Kogyo) or WO0042074 (MILLENIUM PHARMACEUTICALS);

In an additional preferred embodiment, the medicament comprises an antibody specific for CCL17, and may be a monoclonal antibody.

5 In an additional preferred embodiment, the medicament comprises an antibody specific for CCL22, and may be a monoclonal antibody.

In another embodiment, the medicament comprises an antibody which may be a Fab fragment wherein said Fab fragment may be selected from the group consisting of: scFv, F(ab')₂, Fab, Fv and Fd fragments; or CDR3 regions.

10

The fragment antigen binding (Fab fragment) is a region on an antibody which binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain. These domains shape the paratope—the antigen binding site—at the amino terminal end of the monomer. The two variable domains bind the 15 epitope on their specific antigens.

20 Fc and Fab fragments can be generated. The enzyme papain can be used to cleave an immunoglobulin monomer into two Fab fragments and an Fc fragment. The enzyme pepsin cleaves below the hinge region, so a F(ab')₂ fragment and a Fc fragment may be formed. The variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv), which is only half the size of the Fab 25 fragment yet retains the original specificity of the parent immunoglobulin.

30 A complementarity determining region (CDR) is a short amino acid sequence found in the variable domains of antigen receptor (e.g. immunoglobulin and T cell receptor) proteins that complements an antigen and therefore provides the receptor with its specificity for that particular antigen. Most of the sequence variation associated with immunoglobulins and T cell receptors are found in the CDR regions, these regions are sometimes referred to as hypervariable domains. Among these, CDR3 shows the greatest variability as it is encoded by a recombination of the VJ regions.

In another embodiment, the medicament comprises antibodies that may be humanised or chimeric antibodies.

Humanized antibodies or chimeric antibodies are a type of monoclonal antibody that are synthesized using recombinant DNA technology to circumvent the clinical problem of immune response to foreign antigens. The standard procedure of producing monoclonal antibodies yields mouse antibodies. Although murine 5 antibodies are very similar to human antibodies the differences are significant enough that the human immune system recognizes mouse antibodies as foreign, rapidly removing them from circulation and causing systemic inflammatory effects.

Humanized antibodies may be produced by merging the DNA that encodes the 10 binding portion of a monoclonal mouse antibody with human antibody-producing DNA. Mammalian cell cultures are then used to express this DNA and produce these part-mouse and part-human antibodies that are not as immunogenic as the purely murine variety.

15 Modifications may be made to monoclonal antibodies that bind only to cell-specific antigens and preferably induce an immunological response against the target cancer cell. Such monoclonal antibodies are preferably modified for delivery of a toxin, radioisotope, cytokine or other active conjugate.

20 In another aspect of antibody technology, bispecific antibodies may be designed that can bind with their Fab regions both to target antigen and to a conjugate or effector cell. Also, all intact antibodies can bind to cell receptors or other proteins with their Fc region.

25 The production of recombinant monoclonal antibodies may also involve technologies, referred to as repertoire cloning or phage display/yeast display. These may involve the use of viruses or yeast to create antibodies, rather than mice. These techniques rely on rapid cloning of immunoglobulin gene segments to create libraries of antibodies with slightly different amino acid sequences from which antibodies 30 with desired specificities can be selected. This process can be used to enhance the specificity with which antibodies recognize antigens, alter their stability in various environmental conditions, increase their therapeutic efficacy, and modulate their detectability in diagnostic applications.

The invention includes a method of treating or preventing malignant disease in an individual suffering from cancer comprising treating the individual with an effective amount of a small molecule inhibitor of CCR4 and/or CCL17 and/or CCL22. The invention therefore provides the use of small molecule inhibitor of CCR4 and/or 5 CCL17 and/or CCL22 for the manufacture of a medicament for the treatment or prevention of cancer in an individual suffering from cancer.

Embodiments of this aspect of the invention are, for example, the small molecule inhibitors disclosed in WO04007472 (ONO PHARMACEUTICAL CO.), 10 WO05023771 (ONO PHARMACEUTICAL CO.), WO02094264 (TULARIK INC.), WO0230358 (TULARIK / CHEMOCENTRYX), WO0230357 (CHEMOCENTRYX), WO051236976 (ASTELLAS PHARMA INC.), WO05085212 (YAMANOUCHI PHARMACEUTICAL CO., LTD.), WO05082865 (YAMANOUCHI PHARMACEUTICAL CO., LTD.), WO04108717 15 (ASTRAZENECA AB), EP1633729 (ASTRAZENECA AB) or WO03014153 (TOPIGEN PHARMACEUTIQUE INC.)

The invention also includes a method of treating or preventing malignant disease in an individual suffering from cancer comprising treating the individual with an 20 effective amount of an agent that modulates the activity of CCR4 and/or CCL17 and/or CCL22. The invention therefore provides the use of an agent that modulates the activity of CCR4 and/or CCL17 and/or CCL22 for the manufacture of a medicament for the treatment or prevention of cancer in an individual suffering from cancer.

25 Embodiments of this aspect of the invention are, for example, the CCR4 modulating agents as disclosed in WO0041724A1 (LEELAND STANFORD / LEUKOSITE);

In preferred aspects, the method and use of the invention are for the treatment of 30 cancer, preferably selected from the group consisting of bronchial, nasopharyngeal, laryngeal, small cell and non-small cell lung, skin (e.g. melanoma or basal cell carcinoma), brain, pancreatic, neck, lung, kidney, liver, breast, colon, bladder, oesophagus, stomach, cervical, ovarian, germ cell and prostate. More preferably the cancers are cancers of the cervix, oesophagus, kidney, brain, breast and ovary.

In particularly preferred treatments the cancer is cervical cancer, preferably squamous cell carcinoma (SCC).

5 In particularly preferred treatments the cancer is oesophageal cancer, preferably squamous oesophageal carcinoma.

In another aspect, the invention provides a method of screening for anti-cancer agents comprising the steps of:

10 a) providing test cells that express the CCR4 receptor and that are capable of, or are in the process of, proliferation,
b) exposing the test cells to a candidate agent for a period of time,
c) measuring proliferation of the test cells, whereby a decrease in any proliferation in the test cells identifies an anti-cancer agent and/or increased or continued proliferation of the test cells identifies a poor or inactive anti-cancer agent.

15

In other aspects, the invention provides a method of screening for anti-cancer agents comprising the steps of:

20 a) providing test cells expressing the CCR4 receptor and that are capable of, or are in the process of, proliferation,
b) providing at least first and second aliquots of said cells,
c) exposing said first aliquot to a candidate agent for a period of time,
d) not exposing said second aliquot to the candidate agent for the period of time,
25 e) measuring the degree of proliferation of the cells in the first and second aliquots, whereby a decrease in any proliferation of the cell(s) in the first aliquot relative to the cell(s) in the second aliquot identifies an anti-cancer agent and/or increased or continued proliferation of the cell(s) in the first aliquot relative to the cell(s) in the second aliquot identifies a poor or inactive anti-cancer agent.

30

In certain preferred embodiments, the test cells are induced to proliferate, preferably prior to exposure to the candidate agent.

In other preferred embodiments, the test cells are induced to proliferate by the addition of a ligand of the CCR4 receptor.

In another aspect, the invention provides a method of screening for anti-cancer agents comprising the steps of:

- 5 a) providing test cells that express the CCR4,
- b) exposing the test cells to a candidate agent for a period of time,
- c) measuring the level of a secreted protein or signalling molecule of the test cells, whereby a decreased level of the secreted protein or signalling molecule identifies an anti-cancer agent and/or no decrease or an increased level of
- 10 secreted molecule or signalling molecule identifies a poor or inactive anti-cancer agent.

In other aspects, the invention provides a method of screening for anti-cancer agents comprising the steps of:

- 15 a) providing test cells expressing the CCR4,
- b) providing at least first and second aliquots of said cells,
- c) exposing said first aliquot to a candidate agent for a period of time,
- d) not exposing said second aliquot to the candidate agent for the period of time,
- 20 e) measuring the level of a secreted protein or signalling molecule of the test cells in the first and second aliquots, whereby a decreased level of the secreted protein or signalling molecule by the cell(s) in the first aliquot relative to the cell(s) in the second aliquot identifies an anti-cancer agent and/or no decrease or an increased level of secreted molecule or signalling molecule from the cell(s) in the first aliquot relative to the cell(s) in the second aliquot identifies a poor or inactive anti-cancer agent.
- 25

In preferred embodiments, the secreted protein or signalling molecule is a cytokine or chemokine.

30 In other preferred embodiments, the level of the secreted protein or signalling molecule is measured at any time before, during or after exposure of the test cells to the candidate agent.

In certain preferred embodiments, test cells are induced to secrete a particular protein, or other signalling molecule, preferably a chemokine or cytokine, preferably prior to exposure to the candidate agent.

5 In other preferred embodiments, test cells are induced to secrete a particular protein, or other signalling molecule, preferably a chemokine or cytokine, by the addition of a ligand of the CCR4 receptor.

In another aspect, the invention provides a method of screening for anti-cancer
10 agents comprising the steps of:

- a) providing test cells that are expressing the CCR4 receptor and that are capable of, or are in the process of, migration.
- b) exposing the test cells to a candidate agent for a period of time.
- c) simultaneously or subsequent to the period of exposure, providing conditions suitable for cell migration, and measuring any migration of exposed cells, whereby reduced or absent migration in the exposed cells identifies an anti-cancer agent and/or increased or continued migration of the test cells identifies a poor or inactive anti-cancer agent.

20 A method of screening for anti-cancer agents comprising the steps of:

- a) providing test cells expressing the CCR4 receptor and that are capable of, or are in the process of migration,
- b) providing at least first and second aliquots of said cells,
- c) exposing said first aliquot to a candidate agent for a period of time,
- d) not exposing said second aliquot to the candidate agent for the period of time,
- e) simultaneously or subsequent to the period of exposure, providing conditions suitable for cell migration, and measuring the degree of migration of the cell(s) in the first aliquot relative to the cell(s) in the second aliquot, whereby reduced or absent migration identifies an anti-cancer agent and/or increased or continued proliferation of the cell(s) in the first aliquot relative to the cell(s) in the second aliquot identifies a poor or inactive anti-cancer agent.

Chemotaxis, is the phenomenon in which bodily cells, bacteria, and other single-cell or multicellular organisms direct their movements according to certain chemicals in

their environment. This is important for bacteria to find food (e.g. glucose) by swimming towards the highest concentration of food molecules, or to flee from poisons (e.g. phenol). In multicellular organisms, chemotaxis and cell migration are critical to development as well as normal function. In addition, it is known in the art 5 that mechanisms that allow chemotaxis and cell migration in animals can be subverted during cancer metastasis.

Chemotaxis is called positive if movement is in the direction of a higher concentration of the chemical in question, and negative if the direction is opposite.

10

In haptotaxis the gradient of the chemoattractant is expressed or bound on a surface, in contrast to the classical way of chemotaxis when the gradient develops in a soluble space.

15 Necrotaxis embodies a type of chemotaxis when the chemoattractant molecules are released from necrotic or apoptotic cells. Depending on the chemical character of released substances necrotaxis can accumulate or repel cells, which underlines the pathophysiological significance of this phenomenon.

20 In certain preferred embodiments, the test cells are induced to migrate, preferably prior to exposure to the candidate agent.

In other preferred embodiments, the test cells are been induced to migrate by the addition of a ligand of the CCR4 receptor.

25

Cell migration and cell invasion assays measure the ability of certain cell types to move through a porous membrane or matrix toward a chemoattractant or growth factor. Cell migration and invasion may be critical processes in angiogenesis and 30 tumour metastasis. Cell invasion may be measured in one or more dimensions by using suitable culture conditions and a suitable porous matrix for the cells to move through.

In accordance with preferred screening methods, cell invasion may be measured preferably using a matrigel Boyden chamber.

In the method aspects of the invention defined herein the ligand may be CCL17 and/or the ligand may be CCL22.

5 In another aspect, the invention provides a method of screening for anti-cancer agents comprising the steps of:

- a) providing cancer cells that express the CCR4 receptor,
- b) culturing the cancer cells under conditions that result in at least some cancer cell death,
- 10 c) exposing the test cells to a candidate agent for a period of time,
- d) measuring death of cancer test cells, whereby no or no significant increase in cell death in the test cells identifies a poor or inactive anti-cancer agent and/or increased cell death identifies an anti-cancer agent.

15 In other aspects, the invention provides a method of screening for anti-cancer agents comprising the steps of:

- a) providing cancer cells that express the CCR4 receptor,
- b) providing at least first and second aliquots of said cells,
- c) culturing the cancer cells under conditions that result in at least some cancer cell death,
- 20 d) exposing said first aliquot to a candidate agent for a period of time,
- e) not exposing said second aliquot to the candidate agent for the period of time,
- f) measuring death of cancer test cells in the first and second aliquots, whereby no or no significant increase in cell death in the first aliquot relative to the cell(s) in the second aliquot identifies a poor or inactive anti-cancer agent and/or increased cell death in the first aliquot relative to the cell(s) in the second aliquot identifies an anti-cancer agent.

25 In other preferred embodiments the exposure of the test cells or cancer cells to candidate agent may be before or after the change in culture conditions.

30 In preferred embodiments or methods of screening for anti-cancer agents, the test cells or cancer cells are capable of, or are in the process of, proliferation.

In methods of screening for anti-cancer agents, the cell or cells may be from a tumour biopsy sample or may be cervical cancer cell(s), e.g. C-41 (ATCC, Rockville MD, USA) or another cell line endogenously expressing CCR4.

5 The invention will now be described in detail, including by way of experimental examples and with reference to the drawings in which:

BRIEF DESCRIPTION OF THE DRAWINGS

10 **Figure 1** - Expression of CCR4 mRNA is increased in malignant cervical biopsies compared with normal tissues.
(A) Summary of the percentage of samples expressing CC and CXC chemokine receptor mRNA in non-neoplastic (white bars) and malignant (black bars) cervical tissue after ribonuclease protection assay (RPA) for mRNA expression.
15 (B) RPA of non-neoplastic tissue samples 1 to 14 and malignant tissues: Adenocarcinoma biopsies, samples 1 to 4 and squamous cell carcinoma (SCC) biopsies, samples 1 to 11. Stages of adenocarcinoma tissues were: 1 to 3, 1B1; 4, 1B2. Stages of SCC were: 1, 1A2; 2 to 8-11, 1B1; 9, 1B2 and 10, 2A.
20 (C) Up-regulation of CCR4 gene expression in epithelial and stromal compartments when compared to their non-neoplastic counterparts. mRNA expression in non-neoplastic cervical tissue was used as a baseline to compare malignant tissue mRNA and is represented as value “1”.

25 **Figure 2** - Immunohistochemistry for CCR4 during malignant progression of the cervix
CCR4 protein expression in the stroma of (A) non-neoplastic cervical tissue, 200x; (B) CIN 200x; (C) invasive cervical tissue, 200x. CD68+ protein expression in (D) normal, 400x; (E) CIN, 200x; and (F) invasive cervical cancer, 400x. FoxP3+ protein staining in (G) non-neoplastic cervical tissue, 200x; (H) CIN, 400x; and (I) invasive cervical cancer, 400x. Epithelial CCR4 protein expression in (J) non-neoplastic, 200x; (K) CIN, 400x and (L) invasive cervical cancer, 400x.

Figure 3 – Immunohistochemistry score for CCR4, CD68 and FoxP3 positive cells during malignant progression of the cervix

(A) Total score for epithelial cell (black bars) and stromal cell (white bars) staining for CCR4, calculated by ‘positivity’ X ‘intensity’ in normal (n=23), CIN (n=63) and

5 SCC (n=45), recurrent cancer (n=15), lymph node metastasis (n=10) and adenocarcinoma (n=10). (B) Mean CD68+ score (+SE) of intra- and peritumoral macrophage infiltration in normal (n=11), CIN (n=16), adenocarcinomas (n=16), recurrent cancer (n=24) and metastatic deposits in lymph nodes (n=11); ** p<0.001; * p<0.005. (C) Mean FoxP3+ score (+ SE) of intra-and peritumoral Treg cell

10 infiltration in normal (n=11), CIN (n=16), SCC (n=44), adenocarcinomas (n=16) recurrent cancers (n=24) and metastatic deposits in the lymph node (n=11), * p<0.01.

(D) Total CCR4 score on epithelial cells (black bars) and stromal cells (white bars) calculated by ‘positivity’ X ‘intensity’ in CIN I (n=26), CIN II (n=19) and CIN III (n=17).

15 **Figure 4 - mRNA and protein expression of the CCR4 ligand CCL22 in normal, CIN and SCC cervix**

(A) CCL22 mRNA expression levels as assessed by quantitative Real Time RT-PCR in normal (n=14) and SCC (n=11) cervical biopsies (P=0.43). CCL22 protein

20 expression in (B) non-neoplastic, 200x; (C) CIN, 200x and (D) SCC, 200x cervical tissues. (E) Total CCL22 score of epithelial cells (black bars) and stromal cells (white bars) calculated by ‘Positivity X Intensity’ in normal (n=16), CIN (n=17), SCC (n=19) and adenocarcinomas (n=5) samples of the cervix.

25 **Figure 5 - mRNA and protein expression of the CCR4 ligand CCL17 in normal, CIN and SCC cervix**

(A) CCL17 mRNA expression levels as assessed by quantitative Real Time RT-PCR in normal (n=7) compared with SCC (n=11) cervical biopsies (P=0.02). CCL17 protein expression in (B) non-neoplastic, 200x; (C) CIN, 200x and (D) SCC, 200x.

30 (E) Total CCL17 score of epithelial cells (black bars) and stromal cells (white bars) calculated by ‘positivity X intensity’ in normal (n=21), CIN (n=33), SCC (n=20) and adenocarcinomas (n=4) samples of the cervix.

Figure 6 - CCR4 is functional on the cervical cancer cell line C-41

(A) CCR4, CCL17 and CCL22 protein expression (blue lines) was measured in the C-41 cervical cancer cell line by using flow cytometry. Expression / internalization of CCR4 by C-41 was examined after 100ng/ml (B) of CCL17 and (C) CCL22 stimulation (blue line represents CCR4 control at 0 minutes; orange line indicates 5 CCR4 protein expression after stimulation with the appropriate ligand). (D) Migration of the C-41 cervical cancer cell in response to CCL17 and CCL22. Values are the mean \pm SD of 10 determinations, * P < 0.05, ** P < 0.01. (E and F) C-41 growth under suboptimal conditions after stimulation of 1 ng/ml, 10 ng/ml and 100 10 ng/ml of CCL17 and CCL22 for 2, 4 and 6 days. After 6 days C-41 showed in significant growth increase after stimulation with 10 ng/ml CCL17; (P=0.017) and 100 ng/ml CCL17 (P= 0.044), but not with 1ng/ml CCL17 (P=0.383). Stimulation of 1ng/ml CCL22 and 100 ng/ml CCL22 also showed significant increased growth: 1ng/ml CCL22; (P=0.026) and 100 ng/ml CCL22 (P= 0.043), but not with 10 ng/ml CCL22 (P=0.195).

15

Figure 7 - CCR4 expression in carcinogenesis of oesophagus

CCR4 expression in normal (A, x40; D, x40), hyperplastic (B, x100), dysplastic (C, x40; D, x40) epithelial cells of oesophagus and invasive cancer cells (H, x200).

CCR4 expression in the stroma during carcinogenesis of oesophagus: E, normal 20 oesophagus (x200); F, dysplasia I (x200); G, dysplasia III (x200); H, invasive cancer (x200).

Figure 8 – Immunohistochemistry scoring results of CCR4 positive stromal cells during malignant progression of the cervix

25 Scoring was assessed by number of cells positive for CCR4 and by intensity of CCR4 staining. Number of cells was measured as average of 15 HPF: 0 = no CCR4 protein expression; +1 = 1-10 CCR4 positive cells per HPF; +2 = 10-20 positive cells per HPF; +3 (21-30 cells per HPF); +4 (>30 cells). Intensity was measured as: 0 = no expression; 1+ = mild expression; 2++ = moderate expression; 3+++ = strong 30 expression.

Figure 9 - Immunohistochemistry scoring results of CCR4 positive epithelial cells during malignant progression of the cervix

Scoring was assessed by number of cells positive for CCR4 and by intensity of CCR4 staining. 0 = no CCR4 protein expression on epithelial cells; +1 = less than 25% of the section has CCR4 expression; +2 = 26-50% cells positive; +3= 51-75% cells positive; +4 more than 76% cells CCR4 positive. Intensity was measured as: 0 5 = no expression; 1+ = mild expression; 2++ = moderate expression; 3+++ = strong expression

Figure 10 – The results of a screen for CCR4 expression in a wider range of tumours using a human tissue-derived cDNA library (Cancer Research UK). The library 10 contains cDNA generated from RNA isolated from 5-10 tumour samples and 2-5 normal samples for 11 different tumour types: lung, colon, bladder, stomach, pancreas, skin, breast, brain, oesophagus, ovary and prostate. The CCR4 mRNA expression levels were measured using quantitative Real Time RT-PCR.

15 **Figure 11** shows the results of FACS analysis for CCR4 expression on cervical cell lines (C41, C33A) and renal cancer cell lines (786, A498, CAKI). Dashed line: isotype-matched control antibody; grey line CCR4 expression

20 **Figure 12** shows the results of FACS analysis of CCR4 expression on C41 cells after 24 h stimulation with IL-10, TGF- β and FGF. Dashed line: isotype control; grey line CCR4 expression; bold line; CCR4 expression after cytokine stimulation.

25 **Figure 13** shows a cDNA sequence of CCR4. This is SEQ ID NO:1 referred to herein.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have discovered that chemokine receptor CCR4 expression is an early 30 event in carcinogenesis in certain tumour types. Epithelial expression of a receptor for homeostatic chemokines usually present in a tissue may confer a survival advantage on the initiated cell.

The chemokine receptor CCR4 was present on dysplastic non-invasive lesions of the cervix and oesophagus. This was particularly striking in some of the oesophageal cancer samples where CCR4 positive dysplastic areas were clearly seen adjacent to normal epithelial areas in the same section (e.g. Figure 7 C and D).

5

The chemokine receptor CCR4 increased with malignant progression of the cervix. This was not only due to increased infiltration of CCR4-positive macrophages and Treg cells, but also to acquisition of CCR4 expression by epithelial cells. An unexpected finding was that CCR4 was strongly expressed on non-invasive epithelial cells in intraepithelial (CIN) lesions as well as invasive cancer cells. Progression from CIN to invasive disease was associated with increased stromal cell expression of CCR4 ligands CCL17 and 22 and these chemokines stimulated growth and migration of a CCR4-positive cervical cancer cell line (e.g. Figure 4 and Figure 6).

10 CCR4 was also detected on dysplastic as well as invasive epithelial cells in oesophageal cancer, again with CCL17 and CCL22 levels increasing during malignant progression. Changes in CCL17 and 22 gradients aid transition from pre-invasive to invasive disease and attract tumour-promoting leucocytes that help initiated cells evade immune surveillance.

15 20 The two CCR4-binding chemokines, CCL17 and CCL22, were also found on the surface of blood and lymphatic vessels in the tumour biopsies. It was not possible to quantify this but preliminary observations indicate an increase in the intensity of staining with malignant progression.

25 Another element of the CCR4 system is the non-signalling chemokine receptor D6 that has a high affinity for CCL17 and CCL22 [18]; its presence in the tissues would be expected to influence gradients of these chemokines [19].

30 Figure 6 shows that the CCR4 receptor is functional on the cervical cancer cell line C-41. CCR4 can be up-regulated by the microenvironment. CCR4 positive and negative cells were exposed to a number of cytokines (TNF- α , TGF- β , IFN- γ , IL-4 and IL-10) known to be present in the cervical microenvironment and for which receptors were likely to be present on the tumour cells. None of these influenced

CCR4 expression. However, CCR4 mRNA levels, but not protein levels, were up-regulated by co-culture of C-41 cells with macrophages.

CCR4 and D6 are located on chromosome 3p close to where critical cervical cancer

5 tumour suppressor genes are thought to be located with complex aberrations (loss of heterozygosity, homozygosity and gene amplification) reported [25, 26, 27]. While neither *CCR4* nor *D6* are directly implicated in these changes [26], genetic alterations nearby may have an impact on their regulation.

10 EBV-immortalised B cells secrete CCL22 as well as CCL3 and CCL4 [28]. Stable expression of the EBV oncogene LMP1 also induced CCL17 and CCL22 in a B cell line and LMP1-induced CCL17 and CCL22 expression was regulated by NF-kB. It was suggested that induction of these two chemokines by EBV helps malignant cells evade immune surveillance by attracting Th2 and Treg cells. Other oncogenic 15 changes may induce CCL17 and CCL22 production by epithelial cells.

The inventors undertook the detailed quantitation of two components of the mononuclear infiltrate in cervical cancer, specifically CD68+ macrophages and FoxP3+ Tregs. The density of CCR4-positive infiltrating cells increases in CIN 20 compared with normal cervix and increases further in both SCC and adenocarcinomas. CD68+ macrophages follow the same pattern and we found that these were CCR4 positive. Cross talk between macrophages and malignant cells is critical at all stages of cancer progression, influencing malignant cell survival, aiding the angiogenic switch, polarizing leucocytes and aiding malignant cell invasion 25 [29,30,31]. In cancers of the cervix and oesophagus, the chemokines CCL17 and CCL22 play a role in macrophage recruitment whereas in other cancers e.g. ovarian cancer, chemokines such as CCL2 are critical [32].

30 CCL17 and CCL22 are also important in the recruitment of Tregs that increase in a manner parallel to the CD68+ cells in the cervical biopsies. The recruitment of Treg cells to the pre-malignant and malignant lesions fosters immune privilege. For instance, in Hodgkin's Lymphoma, HL, the malignant cells are surrounded by a large number of CCR4+ FoxP3+ lymphocytes [33]. These cells, recruited by the malignant HL cells, create a favourable environment for malignant cells to escape the

host immune system. The inventors think that this is also the case for cervical and oesophageal cancer. Hence not only do the changes in CCL17 and CLL22 gradients directly encourage tumor cell survival and spread but they attract in leucocytes that may also provide survival factors for the tumor cells and contribute to immune
5 privilege/immunosuppression that prevents effective host responses against the tumor.

These data demonstrate that the presence of epithelial CCR4 is both a highly sensitive and highly specific biomarker for both pre-malignant and malignant
10 cervical neoplasia. The role of CCR4 expression in cervical cancer progression is, as yet, unclear though the inventors' data suggests that CCR4 may offer cells protection from apoptotic stimuli within the tumour environment as well as being necessary for tumour cell invasion of the basement membrane. Due to its high sensitivity and selectivity, there is the potential for CCR4 to be used as a diagnostic biomarker for
15 all stages of cervical cancer.

Subsequently the inventors also tested for the expression of CCR4 in 31 samples of oesophageal tumours, another tumour type that has a strong link with inflammation. By IHC they found that CCR4 was not detectable in any normal epithelial
20 oesophageal tissue, but was present in epithelial cells of all pre-invasive and invasive lesions. Due to its high sensitivity and selectivity, there is the potential for CCR4 to be used as a diagnostic biomarker for all stages of oesophageal cancer.

In summary, the chemokine receptor CCR4 and its ligands increase during malignant
25 progression of cervical, oesophageal, kidney, brain, ovarian or breast cancers. Changes in CCR4 and gradients of its ligand have several pro-tumor implications. First CCR4 stimulation increases the growth and survival of the initiated and invasive cancer cells; second, changes in chemokine gradients assists in invasion of the basement membrane and subsequent movement of the malignant cells into the
30 blood vessels or lymphatic system. Finally CCL17 and CCL22 attract the types of cells, including M2 macrophages and FoxP3 Tregs that encourage tumor growth and allow the initiated cells to escape immune surveillance. CCR4 and its ligands may be useful diagnostic markers and therapeutic targets in epithelial neoplasia.

The invention is in part described by way of experimental work and examples, in which the following materials and methods were employed:

EXAMPLES

5

Cervical tissue samples and oesophageal specimens

For the mRNA studies, fifteen tumour biopsies from patients with cervical cancer (11 squamous cell carcinoma, S1-S11, and 4 adenocarcinomas, A1-A4) and 14 samples of non-neoplastic cervical tissue (N1-N14) were obtained during surgery and snap-frozen in liquid nitrogen. Diagnosis was made by the pathology department of Barts and The London NHS Trust. Patient samples were divided according to the FIGO classification (stage I, II, III, IV) and tumour biopsies were classified according to increasing grade of nuclear atypia (1, 2, 3) or as well, moderately, or poor differentiation.

For immunohistochemistry, paraffin embedded samples (n=166) from 150 different patients were obtained from Barts and The London NHS Trust and the Clinical Centre of Serbia, Belgrade. Access to fresh and paraffin-embedded human samples satisfied the requirements of the East London and City Health Authority Research Ethics Subcommittee (LREC no. T/02/046).

Resected specimens from thirty-one patients with primary squamous oesophageal carcinoma were also included in this paper. These patients were from a high-risk area for oesophageal carcinoma in Anyang City, Henan Province, China. All patients received surgical treatment at the Department of Surgery of the Central Hospital of Anyang. None of these patients had undergone chemotherapy, radiotherapy or immunomodulatory therapy before surgery. Samples were taken from macroscopically cancerous and the corresponding normal areas of the same cancer patient. The tissues were fixed in PBS containing 10% neutral-buffered formalin.

RNA extraction and RNase protection assay (RPA)

Cervical tissue biopsies were homogenised using a liquid nitrogen-cooled mill 6750 (Glen Creston Ltd, Stanmore) and then solubilised in Tri Reagent™ (Sigma, Poole, UK). Extracted RNA was treated with 10 units DNase (Pharmacia, St Albans, UK) following the manufacturers instructions. RPA was performed using Riboquant® 5 hCR5 and hCR6 template sets (BD Pharmingen, Oxford, UK) and [α 32P] UTP (Amersham International plc, Aylesbury, UK). RNase-protected fragments were run on an acrylamide-urea sequencing gel (BioRad Laboratories Ltd, Hemel Hempstead, UK), adsorbed to filter paper and dried under vacuum. Autoradiography was performed using Kodak Biomax MS film with a Transcreen LE intensifying screen 10 (Sigma).

Microdissection and Gene array

Paraffin-embedded cervical tissues were cut under RNase-free conditions and 15 mounted onto UV-treated PALM® membrane slides (PALM, Microlaser Technologies, Germany). These were then deparaffinised in xylene and rehydrated through graded alcohols. Samples were stained for 1 min with Mayer's haematoxylin solution, dehydrated and air-dried before processing. Sections were 20 laser-microdissected following the manufacturer's protocol. Briefly, areas of interest were laser microdissected and catapulted into a microfuge cap containing Protein Kinase (PK) buffer. Approximately 500-5000 cells were captured in each session. Laser microdissected cells were dissolved in 100 μ l PK Buffer mixed with 5 μ l PK. Total RNA was then extracted using the Paraffin block RNA isolation kit (1902, 25 Ambion, USA) according to the manufacturer's instructions. cDNA was amplified as described above and analysed using custom-made microfluidic gene array cards (PE Applied Biosystems) according to the manufacturer's instructions.

The gene expression profile of individual genes in seven cervical tumour samples was compared to five normal cervical samples. The gene expression levels in the 30 normal epithelial or stromal cells samples was used as a baseline value of "1" and was compared with the average value of either tumour epithelial cells or tumour stromal cells respectively. The laser microdissected tumour samples comprised of one sample from stage 1A2 and 2B, and five of stage 1B1.

Immunohistochemistry

Paraffin-embedded sections (4µm) were stained for CCR4, CCL17 and CCL22.

5 Briefly, sections were dewaxed in xylene and dehydrated through an ethanol gradient. Following PBS washing the antigen was exposed using Target Retrieval Solution (S1700, DAKO) at 95°C for 20 min or Antigen Unmasking Solution (H-3300, Vector) for 9 min in a microwave. Sections were blocked with normal rabbit or goat serum for 30 min and incubated overnight at 4°C with the primary antibody:
10 CCR4 (1:300, ab1669, AbCam, Cambridge), CCL17 (1:50, ab9816-50, AbCam, Cambridge) and CCL22 (1:20, 500-P107, Peprotech). Following incubation with a biotinylated secondary antibody (anti-goat or anti-rabbit IgG, 1:200, Vector) for 30 min at room temperature, antigens were revealed with 3,3'-diaminobenzidine (DAB; Sigma). Slides were then counterstained with haematoxylin, dehydrated and
15 mounted. Omission of the primary antibody was used as a negative control. To check specificity of the CCR4 antibody, some CCR4-negative cells were transfected with cDNA for this chemokine receptor. The CCR4 antibody detected surface protein only on the successfully transfected cells.

20 Double staining, CD68, FoxP3, SR-A: Scoring methods and categories

For assessment of CCR4, CCL17 and CCL22 expression on non-malignant and malignant epithelial cells, each sample was assessed semi-quantitatively with the following scoring system: 0 (no positive protein expression), +1 (<25% of the cross-section on average has positive expression), +2 (26-50%), +3 (51-75%), +4 (>76%).
25 The intensity of positive cells was analysed as follows: 0 (no expression), 1 (mild expression), 2 (moderate expression), 3 (strong expression). Scoring of CCR4, CCL17 and CCL22 expression in tumour stroma (intratumoral infiltrating cells) and the invasive border of the tumour (peritumoral infiltrating cells) was performed based on the 'running mean' method [43]. Necrotic areas were avoided. A total of
30 15 high-power fields (X400 magnification) were counted. Five scales were set up as follows: 0 = no CCR4 protein expression; +1 = 1-10 CCR4 positive cells per HPF; +2 = 10-20 positive cells per HPF; +3 (21-30 cells per HPF); +4 (>30 cells). The

overall staining result was obtained by calculating 'percentage' X 'intensity'. The IHC scoring on tumour and infiltrating cells was performed by a board-certified pathologist (YW).

5 Cervical cancer cell line culture

The cervical cancer cell line C-41 (ATCC, Rockville, MD, USA) was cultured in DMEM medium supplemented with 10% FCS. In some experiments cells were stimulated with 1, 10, 100, or 1000 ng/ml of CCL17 or CCL22 (PeproTech, London, 10 UK). Proliferation and migration were assessed using methods described previously [11].

Statistical analysis

15 Statistical significance was evaluated using unpaired t-test with Welch's correction (Instat software, San Diego, CA). A P value of <0.05 was considered significant.

Experiment 1 - Ribonuclease protection assay for chemokine receptors

20 Ribonuclease protection assays (RPA) were used to screen for 13 chemokine receptor mRNAs in fresh-frozen biopsies of human cervical tissue. As can be seen from the summary graph in Figure 1A, a range of chemokine receptor mRNAs was found in cervical tissue extracts with some discrete differences between the non-neoplastic and the malignant biopsies. Of particular interest was the chemokine receptor CCR4, which was present in the malignant cervix but not in extracts from 25 non-neoplastic cervical biopsies (Figure 1B).

As chemokine receptor expression was examined on whole tissue extracts containing a mixed population of stromal cells and epithelial cells, we next investigated the 30 cellular source of the CCR4 mRNA. mRNA was extracted from laser microdissected stromal and epithelial cell areas of normal and malignant cervical biopsies, and semi-quantitative Real Time RT-PCR was used to analyse CCR4 expression with 18S rRNA as a control. As shown in Figure 1C, CCR4 mRNA was up-regulated in

stromal areas from malignant tissues when these were compared to their non-neoplastic counterparts. In addition, and unexpectedly, CCR4 mRNA was also up-regulated in extracts from the malignant epithelial cell areas compared to normal epithelium.

5

To investigate further these observations relating to CCR4 mRNA, we stained a cohort of biopsies for CCR4 using immunohistochemistry, IHC. We assessed CCR4 protein expression in 166 samples of paraffin embedded cervical tissues from 150 different patients: nonneoplastic, n=23; CIN I, n=30; CIN II, n=17; CIN III, n=16; 10 SCC, n=45; recurrent tumour, n=15; lymph node metastasis (LN mets), n=10; adenocarcinoma, n=10. Both leucocytes and epithelial cells expressed CCR4 protein. To quantify our results, an IHC score was calculated by multiplying the 'positivity' and 'intensity' (see the description of methods and Figures 8 and 9 for a more details).

15

Experiment 2 - CCR4 protein is found on infiltrating leucocytes in human cervical biopsies.

As shown in Figure 2 (A-C), leucocytes in the stromal areas of the biopsies stained positive for CCR4. The IHC score for CCR4 positivity in the stromal areas is 20 summarised in Figure 3A (white bars). The non-neoplastic tissues were negative for CCR4 leucocytes (Figures 2A, 3A). There were more CCR4 expressing stromal cells in the CIN samples (Figure 2 B, 3A) and this increased further in the invasive neoplastic cervical samples (Figure 2 C, 3A). The intensity of CCR4 expression on 25 the infiltrating leucocytes also increased with malignant progression. In non-neoplastic tissues this was mild; intensity was moderate to strong in CIN and adenocarcinomas, and intensity was strong in invasive SCC, recurrent tumours and lymph node metastases (Figure 8).

30

The stroma consists of various cell types, and tests were carried out to ascertain which of the infiltrating cells contributed to CCR4 expression. As macrophages and Treg cells express CCR4, CCR4 protein expression was examined in these two cell types and also counted the number of CD68+ macrophages and FoxP3+ Treg cells in the tissue biopsies were counted.

Experiment 3 - CCR4 positive macrophages and Treg cells increase with malignant progression.

5 The number of CD68+ macrophages and FoxP3+ Tregs increased with malignant progression of the cervix. As shown in Figure 2 D-I there were few CD68 and FoxP3 cells in biopsies of normal cervix, but the numbers increased in CIN and both cell types were prominent in invasive cancers.

10 The numbers of CD68+ and FoxP3+ cells were then counted in the 122 and 33 biopsies respectively. As shown in Figure 3B there was a significant ($p<0.001$) increase in CD68+ cells in CIN lesions compared to normal cervix. The number of 13 CD68+ cells further increased in SCC, adenocarcinoma, recurrent cancers and lymph node metastases ($P<0.001$, and for LN mets $P <0.05$, compared to normal cervix). A similar increase in FoxP3+ cells occurred with malignant progression with SCC, adenocarcinomas and lymph node metastases all showing significant increases in the FoxP3+ infiltrate compared to normal cervix ($p<0.01$).

15

To study the phenotype of infiltrating CCR4 expressing cells, an assessment was made of cell surface expression of CCR4 by macrophages and Tregs using double immunohistochemical staining for CD68 and FoxP3. This confirmed that CD68+ and FoxP3+ cells also express CCR4 protein (data not shown). A subset of 33 paraffin embedded tissues were also stained for scavenger receptor-A (SR-A) protein (non-neoplastic=10, CIN =10, SCC=10, adenocarcinoma=3). SR-A is a cell surface marker for M2 alternatively activated macrophages [12]. SR-A could not be detected on stromal cells in nonneoplastic lesions but in CIN and invasive cancer, a proportion of the CD-68+ cells expressed SR-A (data not shown).

20

25

These studies show, firstly, that malignant progression of the cervix is associated with an increase in the numbers of CD68+ macrophages and FoxP3+ Treg cells. These cells could provide pro-tumour growth factors for the malignant cells and also help create an immunosuppressive microenvironment that would help transformed cells evade immune surveillance. Secondly, these results showed that the original observation of an increase in CCR4 mRNA in malignant compared to normal

30

cervical cancer was due, at least in part, to an increased infiltrate of CCR4 expressing leucocytes, including macrophages and Treg cells.

However, the laser microdissection result showed that CCR4 mRNA was also increased in epithelial areas of the tumours, and when assessing CCR4 protein on infiltrating leukocytes, it was clear that the chemokine receptor was also present on some epithelial cells (see Figure 2B and C). This was unexpected and warranted further investigation.

10 **Experiment 4 - Epithelial cells in cervical biopsies also express CCR4**

In the non-neoplastic cervical biopsies, normal epithelial cells did not express CCR4 (Figure 2A). However epithelial cells in over 90% of the CIN cases expressed CCR4 (Figure 2B and 2E). 96% of the SCC samples had CCR4-positive epithelial cells (Figure 2C and 2F) and epithelial cells 90% of adenocarcinoma samples were positive for CCR4 (Figure 2G). Malignant epithelial cells in all recurrent tumours and lymph node metastases expressed CCR4 protein. Full details of the IHC results for CCR4 protein on epithelial cells are shown in figure 9 and summarised in Figure 2D (black bars). CCR4 expression was not restricted to a minority of epithelial cells. 20 Figures 2E-G and 9 show that the majority of malignant epithelial cells in cervical biopsies of CIN and invasive cancer were CCR4 positive.

More detail relating to the IHC score for different stages of CIN is shown in Figure 2 H. This shows that epithelial CCR4 expression was essentially unchanged through 25 progression from CINI to III but that stromal levels of CCR4 increased from CIN I- III

30 **Experiment 5 - Statistical analysis of CCR4 expression during cervical cancer progression**

Statistical analysis of the data in figures 8 and 9 showed that CIN lesions showed a significant up-regulation of CCR4 protein in both epithelial ($P=0.0001$) and stromal ($P=0.0001$) compartments when compared to non-neoplastic cervical tissues. CCR4 expression in invasive SCC was also significantly increased in both the epithelial

($P=0.0001$) and stromal compartments ($P=0.0001$) when compared to non-neoplastic tissues. Also in adenocarcinoma samples, CCR4 was up-regulated 15 on epithelial ($P=0.0006$) and stromal cells ($P=0.0050$) when compared to non-neoplastic cervical tissue.

5

Experiment 6 - CCL22 mRNA and protein levels change with malignant expression

In normal tissues, CCL22 is a product of macrophages, monocytes, DC, B and T cells [13, 14]. It is also found in epithelial tissues; for instance intestinal epithelium 10 constitutively produces CCL22 that can be further up-regulated by inflammatory cytokines such as TNF- α [15]. mRNA was isolated from 14 biopsies of normal cervix, 11 SCC and 4 adenocarcinomas and CCL22 levels assessed by real time RT PCR. As shown in Figure 4A CCL22 mRNA levels were lower in the malignant tissues compared with the normal biopsies but this was not significant ($P = 0.43$). A 15 total of 52 samples of paraffin embedded cervical tissues from 50 different patients were assessed for CCL22 protein: non-neoplastic, $n=16$; CIN, $n=17$; SCC, $n=19$. In all cervical biopsies, CCL22 was detected in the epithelial cells (Figure 4B -D). Fourteen of 16 normal samples, 15/17 CIN, 14/19 SCC had CCL22 positive 20 epithelial cells. Infiltrating leucocytes in all biopsies contained CCL22 (Figure 4C, D). The epithelial IHC score declined slightly between the CIN lesions and SCCs (Figure 4E black bars). However, the stromal score for CCL22 increased from normal to CIN and SCC (Figure 4E white bars).

Experiment 7 - CCL17 mRNA and protein levels change with malignant expression

25

In normal tissues, CCL17 is expressed by vascular and lymphatic endothelial cells but is also produced by macrophages, DC and keratinocytes [16, 17, 55] mRNA was isolated from 14 biopsies of normal cervix, 11 SCC and 4 adenocarcinomas and 30 CCL17 levels assessed by real time RT-PCR. As shown in Figure 5A levels of CCL17mRNA were higher in SCC compared to normal cervix. A total of 74 samples of paraffin embedded cervical tissues from 70 different patients were assessed for CCL17 protein: non-neoplastic, $n=21$; CIN, $n=33$; SCC, $n=20$. Normal cervical biopsies had low levels of CCL17 in a minority of samples both the

epithelium and stroma (Figure 5B). Only 2/19 normal samples had CCL17 positive cells in the epithelium compared with 23/33 CIN samples and 13/20 SCC. The number of stromal cells that were CCL17 positive was increased in CIN (Figure 5C) and SCC (Figure 5D) compared to normal samples. Six of 21 normal biopsies had 5 CCL17 positive stromal cells compared to 25/33 CIN and 15/20 SCC. The epithelial and stromal CCL17 IHC score was increased in CIN and SCC compared to normal biopsies (Figure 5E). When the IHC scores from individual biopsies were analysed, there was a statistically significant difference in CCL17 IHC score in stroma from 10 CIN ($P=0.001$) and SCC ($P=0.002$) compared to normal biopsies. There was also a difference in the IHC scores in epithelial areas of CIN ($P=0.001$) and SCC ($P=0.009$) compared to normal. These data show that chemokine gradients changed with the transition from intraepithelial neoplasia to invasive disease.

Experiment 8 - CCR4 is functional on cervical cancer cells

15 To investigate the biological significance of CCR4 expression on cervical cancer cells a number of cervical cancer cell lines (CaSki, Me180, Hela-Ohio, Hela-S3, Siha, C33A, C41-1) were screened for CCR4 expression. The cell line C-41 expressed cell surface CCR4 in a constitutive manner (Figure 6A). Using FACS analysis it was shown that C-41 cells expressed cell surface CCR4. This cell line 20 also had intracellular CCL22 protein but the other CCR4 ligand CCL17 was not present (Figure 6A). Following stimulation with 100 ng/ml CCL22, cell surface CCR4 protein was internalized on C-41 cells after 2 hours and returned back to the surface after 3 hours (Figure 6B). Following stimulation with 100 ng/ml CCL17, cell 25 surface CCR4 protein was also internalized on C-41 cells after 2 hours and returned back to the surface after 3 hours (Figure 6C). C-41 cells demonstrated a typical bell-shaped chemotactic response towards both CCL17 and CCL22 in trans-well migration assays (Figure 6D). At 10 ng/ml, CCL17 induced significant migration ($P=0.036$) and also at 100 ng/ml and 1000ng/ml ($P=0.0006$ and $P=0.0004$ respectively). Similar results were seen with CCL22 at 10 ng/ml ($P=0.0081$), 30 10ng/ml ($P=0.0009$) and at 1000 ng/ml ($P=0.0348$).

C-41 cells showed increased proliferation after stimulation with either 10 ng/ml (P=0.017) or 100ng/ml (P= 0.044) of CCL17. 1ng/ml CCL22; (P=0.026), 100 ng/ml CCL22 (P= 0.043), but not 10 ng/ml CCL22 (P=0.195), also simulated C-41 cell growth (Figure 5C and D). CCR4 was therefore functional on this cervical cancer cell line, suggesting that it may also be functional *in vivo*.

Experiment 9 - CCR4 is expressed on epithelial and stromal cells during malignant progression of the oesophagus

10

It was unknown as to whether the expression of CCR4 and changes in chemokine ligand were specific for cervical cancer or whether they were seen in any other epithelial malignancies that have a link with inflammation. Cancer of the oesophagus is an epithelial cancer where examples of all stages of neoplastic

15

progression can be readily obtained, often simultaneously from the same patient. CCR4 expression was examined in 31 specimens from patients with oesophageal cancer. In 27 of the cases, all stages of carcinogenesis of the oesophagus: normal, hyperplasia, dysplasia, *in situ* carcinoma and invasive cancer, were present in biopsies from the same patient. Four of 31 cases had pre-invasive

20

lesions without invasive cancer areas. As shown in Figure 7A, there was no detectable CCR4 expression in normal epithelial cells of oesophagus, apart from a few CCR4-positive cells around the basal layer of hyperplastic epithelium (Figure 7B). In 30 of 31 cases CCR4 protein was present on epithelial cells in all stages of pre-invasive lesions (Figure 7C,D), that the intensity and percentage of CCR4

25

expressing cells in dysplastic lesions was much higher than in hyperplastic epithelial cells. Epithelial cells in the invasive cancer were also CCR4-positive (Figure 7H).

In some places, there was an abrupt transition between normal and abnormal mucosa (Fig 7C, D). Most interestingly, there were high levels of CCR4 expression in the dysplastic cells, but the cells in the superficial layers, and adjacent normal mucosa

30

were negative. CCR4- positive cells were also present in the stroma, the pattern being the same as in cervical cancer. As shown in Figure 7E, there were few CCR4-positive cells in the normal submucosa; with malignant progression, there were more CCR4 positive cells infiltrating the stroma (Figure 7F-H).

Experiment 10 - CCL17 and CCL22 in oesophageal biopsies

IHC was used to assess CCL17 and CCL22 expression in 23 of the oesophageal
5 samples in which all stages of carcinogenesis were present in each sample. CCL17
was generally absent in both the epithelial and stromal areas of the normal tissues,
although there were a few CCL17-positive cells in the stroma and a minority of
hyperplastic areas. The number of samples containing CCL17-positive epithelial or
stromal cells increased in dysplasia and was highest in invasive areas with 10/23 of
10 these showing some CCL17 positivity. Of particular note was strong CCL17
immunoreactivity on the endothelial cells or blood/lymphatic vessels in the
submucosa of dysplastic but not normal epithelium.

Similar to the observations in cervical cancer, the levels of stromal positivity for
15 CCL22 also increased with malignant progression. Only 1/23 samples showed
CCL22 positive cells in the stroma of the normal areas, but in dysplastic areas and
invasive areas 20/23 and 18/23 samples respectively contained CCL22-positive cells
in the stroma. The stromal cell CCL22 positivity increased with the degree of
dysplasia. Eight of 23 dysplasia I samples had CCL22 positive cells in the stroma;
20 this increased to 19 of 23 samples of dysplasia II and 20/23 samples of dysplasia III.
There was one difference between the cervical and oesophageal epithelium in that
CCL22 was not detected in normal epithelium although it has been reported to be
present in normal intestinal epithelium [15]. Epithelial CCL22 expression increased
with malignant progression of the oesophagus; 0/23 samples were positive in the
25 normal areas, 2/23 hyperplasias, 7/23 dysplasias and 14/23 invasive areas had CCL22
positive epithelial cells. Finally, more endothelial cells of blood vessels within the
stroma of invasive cancer tissues were positive for CCL22 staining compared with
normal and dysplastic epithelium.

30 **Experiment 11 – The results of a screen for CCR4 expression in a wider range of**
tumours

Using a tumour cDNA library (Cancer Research UK) containing cDNA generated
from RNA isolated from 5-10 tumour samples and 2-5 normal samples for 11

different tumour types: lung, colon, bladder, stomach, pancreas, skin, breast, brain, oesophagus, ovary and prostate. The CCR4 mRNA expression levels were measured using quantitative Real Time RT-PCR.

5 CCR4 mRNA levels were significantly elevated in cancers of the cervix, oesophagus, kidney, brain, breast and ovary.

Experiment 12 – Analysis of expression of CCR4 in cervical and renal cancer cell lines

10

Figure 11 shows the results of Fluorescence Activated Cell Scanning (FACS) analysis on cervical (C41, C33A) and renal cancer cell lines using an anti-CCR4 antibody to detect CCR4 expression. All the cell lines expressed CCR4. The dashed lines in Figure 11 show the data for an isotype-matched control antibody.

15

Experiment 13 – Effects of common cytokines on CCR4 expression by tumour cells

The most common cytokines present in a tumour are IL-10, TGF- β , FGF, TNF- α .

The

20 C41 cervical cancer cell line was stimulated in culture with different cytokines (IL-10, TNF- α , TGF- β , FGF; 20 ng/ml) for 24 h. The expression of CCR4 was then determined by FACS analysis. As shown in Figure 12, CCR4 was upregulated in terms of percentage of positive cells after IL-10, TGF- β and FGF stimulation (blue line) when compared with the unstimulated cells (black line). The dashed line shows 25 the data for an isotype control. The bold line shows CCR4 expression after stimulation. The results indicate that tumour microenvironment can induce expression of CCR4 on tumour cells.

References

30 1. Allen, S.J., Crown, S.E., and Handel, T.M. 2006. Chemokine: receptor structure, interactions, and antagonism. *Annu Rev Immunol* 25:787-820.

2. Balkwill, F.R. 2004. Cancer and the chemokine network. *Nature Reviews Cancer* 4:540-550.

3. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. *Nature* 410:50-56.

5 4. Scotton, C.J., Wilson, J.L., Milliken, D., Stamp, G., and Balkwill, F.R. 2001. Epithelial cancer cell migration: a role for chemokine receptors? *Cancer Res* 61:4961-4965.

5 5. Zeelenberg, I.S., Ruuls-Van Stalle, L., and Roos, E. 2003. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma 10 micrometastases. *Cancer Res* 63:3833-3839.

10 6. Balkwill, F. 2004. The significance of cancer cell expression of CXCR4. *Seminars in Cancer Biology* 14:171-179.

7. Burger, J.A., and Kipps, T.J. 2006. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. *Blood* 107:1761-1767.

15 8. Zlotnik, A. 2006. Chemokines and cancer. *Int J Cancer* 119:2026-2029.

9. Meijer, J., Zeelenberg, I.S., Sipos, B., and Roos, E. 2006. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of 20 colon carcinoma in the liver. *Cancer Res* 66:9576-9582.

10. Letsch, A., Keilholz, U., Schadendorf, D., G., A., Asemissen, A.M., Thiel, E., and Scheibenbogen, C. 2004. Functional CCR9 expression is associated with small intestinal metastasis. *J Invest Dermatol* 122:685-690.

25 11. Scotton, C.J., Wilson, J.L., Scott, K., Stamp, G., Wilbanks, G.D., Fricker, S., Bridger, G., and Balkwill, F.R. 2002. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. *Cancer Research* 62:5930-5938.

12. Gordon, S. 2003. Alternative activation of macrophages. *Nature Reviews Immunol* 3:23-35.

30 13. Godiska, R., Chantry, D., Raport, C.J., Sozzani, S., Allavena, P., Leviten, D., Mantovani, A., and Gray, P.W. 1997. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. *J Exp Med* 185:1595-1604.

14. Mantovani, A., Gray, P.A., Van Damme, J., and Sozzani, S. 2000. Macrophage-derived chemokine (MDC). *J Leukoc Biol* 68:400-404.

15. Berin, M.C., Dwinell, M.B., Eckmann, L., and Kagnoff, M.F. 2001. Production of MDC/CCL22 by human intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 280:G1217-G1226.

16. Imai, K., Kobayashi, M., Wang, J., Shinobu, N., Yoshida, H., Hamada, J.,
5 Shindo, M., Higashino, F., Tanaka, J., Asaka, M., et al. 1999. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. *Br J Haematol* 106:905-911.

17. Sallusto, F., Palermo, B., Lenig, D., Miettinen, M., Matikainen, S., Julkunen,
10 I., Forster, R., Burgstahler, R., Lipp, M., and Lanzavecchia, A. 1999. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. *Eur J Immunol* 29:1617-1625.

18. Fra, A.M., Locati, M., Otero, K., Sironi, M., Signorelli, P., Massardi, M.L.,
15 Gobbi, M., Vecchi, A., Sozzani, S., and Mantovani, A. 2003. Cutting Edge: Scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. *J Immunol* 170:2279-2282.

19. Graham, G.J., and McKimmie, C.S. 2006. Chemokine scavenging by D6: a movable feast? *Trends in Immunol* 27:381-386.

20. Woerner, B.M., Warrington, N.M., Kung, A.L., Perry, A., and Rubin, J.B.
2005. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. *Cancer Res* 65:11392-11399.

21. Salvucci, O., Bouchard, A., Baccarelli, A., Deschenes, J., Sauter, G., Simon, R., Bianchi, R., and Basik, M. 2006. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. *Br Ca Res & Treat* 97:275-
25 283.

22. Schmid, B.C., Rudas, M., Reznicek, G.A., Leodolter, S., and Zeillinger, R.
2004. CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. *Br Ca Res & Treat* 84:247-250.

23. Pils, D., Pinter, A., Reibenwein, J., Alfanz, A., Horak, P., Schmid, B.C.,
30 Hefler, L., Horvat, R., Reinthaller, A., Zeillinger, R., et al. 2007. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. *Br J Cancer* 96:485-491.

24. Borrello, M.G., Alberti, L., Fischer, A., Degl'innocenti, D., Ferrario, C.,
Gariboldi, M., Marchesi, F., Allavena, P., Greco, A., Collini, P., et al. 2005.

Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. *PNAS* 102:14825-14830.

25. Braga, E., Senchenko, V., Bazov, I., Loginov, W., Liu, J., Ermilova, V., Kuzubskaya, T., Garkavtseva, R., Mazurenko, N., Kisseljov, F.L., et al. 2002.

5 Critical tumor-suppressor gene regions on chromosome 3p in major human epithelial malignancies: allelotyping and quantitative real-time pcr. *Int J Cancer* 100:534-541.

26. Senchenko, V., Liu, J., Braga, E., Mazurenko, N., Loginov, W., Seryogin, Y., Bazov, I., Protopopov, A., Kisseljov, F.L., Kashuba, V., et al. 2003. Deletion mapping using quantitative real-time PCR identifies two distinct 3-21.3 regions affected in most cervical carcinomas. *Oncogene* 22:2984-2992.

10 27. Acevedo, C.M., Henriquez, M., Emmert-Buck, M.R., and Chuaqui, R.F. 2002.

15 Loss of heterozygosity on chromosome arms 3p and 6q in microdissected 33 adenocarcinomas of the uterine cervix and adenocarcinoma in situ. *Cancer* 94:793-802.

28. Nakayama, T., Hieshima, K., Nagakubo, D., Sato, E., Kakayama, M., Kawa, K., and Yoshie, O. 2004. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. *J Virol* 78:1665-1674.

20 29. Balkwill, F., Charles, K.A., and Mantovani, A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* 7:211-217.

30 30. Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N.F., Pluddemann, A., Charles, K., Gordon, S., and Balkwill, F.R. 2006. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. *J Immunol* 176:5023-5032.

31. Condeelis, J., and Pollard, J.W. 2006. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell* 124:263-266.

30 32. Negus, R.P.M., Stamp, G.W.H., Relf, M.G., Burke, F., Malik, S.T.A., Bernasconi, S., Allavena, P., Sozzani, S., Mantovani, A., and Balkwill, F.R. 1995. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. *J Clin Invest* 95:2391-2396.

33. Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H.,

and Ueda, R. 2006. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. *Cancer Res* 66:5716-5722.

34. Nakamura, E.S., Koizumi, K., Kobayashi, R., Saitoh, Y., Arita, Y.,
5 Nakayama, T., Sakurai, H., Yoshie, O., and Saiki, I. 2006. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. *Clin Exp Metastasis* July 5.

10 35. Ishida, T., Inagaki, H., Utsunomiya, A., Takatsuka, Y., Komatsu, H., Iida, S., Takeuchi, G., Eimoto, T., Nakamura, S., and Ueda, R. 2004. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. *Clin Cancer Res* 10:5494-5500.

15 36. Ishida, T., and Ueda, R. 2006. CCR4 as a novel molecular target for immunotherapy of cancer. *Cancer Sci* 97:1139-1146.

37. Ishida, T., Iida, S., Akatsuka, Y., Ishii, T., Miyazaki, M., Komatsu, H., Inagaki, H., Okada, N., Fujita, T., Shitara, K., et al. 2004. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult Tcell leukemia/lymphoma. *Clin Cancer Res* 10:7529-7539.

20 38. Kleeff J, Kusama T, Rossi DL, Ishiwata T, Maruyama H, Friess H, Büchler MW, Zlotnik A, Korc M. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. *Int J Cancer*. 1999 May 17;81(4):650-7.

25 39. Kimsey TF, Campbell AS, Albo D, Wilson M, Wang TN. Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. *Cancer J*. 2004 Nov-Dec;10(6):374-80.

30 40. Jörer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Hörtl L, Bartsch G, Greil R, Thurnher M. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. *Clin Cancer Res*. 2005 Apr 1;11(7):2459-65.

41. Ferenczi, K., Fuhlbrigge, R.C., Pinkus, J.L., Pinkus, G.S. & Kupper, T.S. Increased CCR4 expression in cutaneous T cell lymphoma. *J Invest Dermatol* 119, 1405-1410 (2002).

42. Baatar, D., Olkhanud, P., Newton, D., Sumitomo, K. & Biragyn, A. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. *J Immunol* 179, 1996-2004 (2007).

5 43. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study.

10 *BMC Ital Cancer*. 2001;1:7. Epub 2001 Jul 16.

44. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ. "CXCR4-SDF-1 signalling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion." *Blood*. 2002 Oct 1;100(7):2597-606.

15 45. Bange, J; Zwick E, Ullrich A. (2001). "Molecular targets for breast cancer therapy and prevention". *Nature Medicine* 7: 548 – 552

[46] Ménard, S; Pupa SM, Campiglio M, Tagliabue E (2003). "Biologic and 20 therapeutic role of HER2 in cancer". *Oncogene* 22: 6570 – 6578

47. Kute, T; Lack CM, Willingham M, Bishwokarma B, Williams H, Barrett K, Mitchell T, Vaughn JP (2004). "Development of herceptin resistance in breast cancer cells". *Cytometry* 57A: 86 – 93.

25 48. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin. *J Invest Dermatol*. 2000 Oct;115(4):640-6.

CLAIMS:

1. A method of obtaining information of predictive or diagnostic character for a cancer patient, comprising the step of measuring the amount and/or activity of chemokine receptor CCR4 expressed by tumour cells in a solid tumour sample or in a non-haematological cell tumour sample taken from the patient, the amount and/or activity of CCR4 providing the information of predictive or diagnostic character.
5
- 10 2. A method as claimed in claim 1, wherein the information of predictive or diagnostic character is obtained by comparing the amount and/or activity of CCR4 in the solid tumour sample or the non-haematological cell tumour sample, with a reference amount and/or level of activity of CCR4.
- 15 3. A method as claimed in claim 1 or claim 2, wherein the reference amount and/or level of activity of CCR4 is measured in one or more non-tumour samples.
4. A method as claimed in claim 3, wherein the, or at least one non-tumour sample is taken from the patient.
20
5. A method as claimed in claim 3, wherein the one or more non-tumour samples are not taken from the patient.
- 25 6. A method as claimed in any of claims 1 to 5, wherein the information is used to predict whether the solid tumour or the non-haematological cell tumour of the patient will be susceptible to an anti-cancer treatment.
7. A method as claimed in any of claims 1 to 5, wherein the patient has received an anti-cancer treatment and measurements of the amount and/or activity of CCR4 in the solid tumour sample or the non-haematological tumour sample of the patient are made before and after the start of treatment, and the information obtained is used to determine whether the solid tumour or the non-haematological cell tumour of the patient has responded to the anti-cancer treatment.
30

8. A method as claimed in any of claims 1 to 5, wherein the information is used in diagnosis of a solid tumour or a non-haematological cell tumour.
9. A method as claimed in any of claims 1 to 5, wherein the information is used to 5 stage a solid tumour or a non-haematological cell tumour.
10. A method of obtaining information of predictive or diagnostic character for a cancer patient whose tumour cells express chemokine receptor CCR4, comprising the step of measuring the amount and/or activity of CCR4 ligand 10 CCL17 and/or CCL22 in a solid tumour sample or in a non-haematological cell tumour sample taken from the patient, the amount and/or activity of CCL17 and/or CCL22 providing the information of predictive or diagnostic character.
11. A method as claimed in claim 10, wherein the information of predictive or 15 diagnostic character is obtained by comparing the amount and/or activity of CCL17 and/or CCL22 in the solid tumour sample or in the non-haematological cell tumour sample with a reference amount and/or level of activity of CCL17 and/or CCL22.
- 20 12. A method as claimed in claim 11, wherein the reference amount and/or level of activity of CCL17 and/or CCL22 is measured in one or more non-tumour samples.
- 25 13. A method as claimed in claim 12, wherein the, or at least one non-tumour sample is taken from the patient.
14. A method as claimed in claim 12, wherein the one or more non-tumour samples are not taken from the patient.
- 30 15. A method as claimed in any of claims 10 to 14, wherein the information is used to predict whether the solid tumour or the non-haematological cell tumour of the patient will be susceptible to an anti-cancer treatment.

16. A method as claimed in any of claims 10 to 14, wherein the patient has received an anti-cancer treatment and measurements of the amount and/or activity of CCL17 and or CCL22 are made before and after the start of treatment and the information obtained is used to determine whether the solid tumour or the non-haematological cell tumour of the patient has responded to the anti-cancer treatment.

5

17. A method as claimed in any of claims 6, 7, 15 or 16, wherein the anti-cancer treatment comprises an agent which modulates or inhibits CCR4 expression or activity.

10

18. A method as claimed in claim 17, wherein the agent which modulates or inhibits CCR4 expression or activity is:

15. (i) an antibody which binds to CCR4; optionally an anti-CCR4 antibody as disclosed in any of WO0041724, WO0164754, WO05035582, WO03018635, WO05053741, WO0042074; or

20 (ii) an antibody which binds to CCR4 ligands CCL17 or CCL22; optionally anti-CCL17 or anti-CCL22 antibodies as disclosed in WO99/15666; or Ishida, T., *et al* (2004) *Clin Cancer Res* 10:7529-7539.

25 (iii) a CCR4 antagonist; optionally a CCR4 antagonist as disclosed in any of WO04007472, WO05023771, WO02094264, WO0230358, WO0230357, WO051236976, WO05085212, WO05082865, WO04108717, EP1633729, WO03014153.

30

19. A method as claimed in any preceding claim, wherein the solid tumour or non-haematological tumour is a cancer selected from cancer of the cervix, oesophagus, kidney, brain, breast, ovary, prostate, stomach or pancreas.

20. The use of an antibody reactive against chemokine receptor CCR4 for detecting the presence or measuring the amount of CCR4 expressed by a solid tumour or a non-haematological tumour in a cancer patient, the presence or amount of CCR4

expressed by the tumour and when detected or measured providing the information of diagnostic character.

21. The use of an oligonucleotide primer or probe capable of hybridizing under

5 stringent conditions to SEQ ID NO:1 for detecting or measuring the amount of expression of CCR4 by cells of a solid tumour or a non-haematological tumour, the presence or amount of CCR4 expressed by the tumour when detected or measured providing the information of diagnostic character.

10 22. A use as claimed in claim 20 or claim 21, wherein the information is used to predict whether the solid tumour or the non-haematological cell tumour of the patient will be susceptible to an anti-cancer treatment; optionally an anti-cancer treatment comprising an active agent as defined in claim 12 or claim 13

15 23. A use as claimed in claim 20 or claim 21, wherein the patient has received an anti-cancer treatment and measurements of the amount and/or activity of CCR4 are made before and after the start of treatment and the information obtained is used to determine whether the solid tumour or the non-haematological cell tumour of the patient has responded to the anti-cancer treatment.

20 24. A use as claimed in claim 20 or claim 21, wherein the information is used for diagnosis of a solid tumour or a non-haematological cell tumour.

25 25. A use as claimed in claim 20 or claim 21, wherein the information is used to stage the solid tumour or the non-haematological cell tumour.

26. A method of treating a cancer patient having a solid tumour or a non-haematological tumour expressing CCR4, comprising administering an effective amount of an agent which modulates or inhibits CCR4 expression or activity.

30 27. A method as claimed in claim 26, wherein the agent which modulates or inhibits CCR4 expression or activity is:

(i) an antibody which binds to CCR4; optionally an anti-CCR4 antibody as disclosed in any of WO0041724, WO0164754, WO05035582, WO03018635, WO05053741, WO0042074; or

5 (ii) an antibody which binds to CCR4 ligands CCL17 or CCL22; optionally anti-CCL17 or anti-CCL22 antibodies as disclosed in WO99/15666; or
Ishida, T., *et al* (2004) *Clin Cancer Res* 10:7529-7539.

10 (iii) a CCR4 antagonist; optionally a CCR4 antagonist as disclosed in any of WO04007472, WO05023771, WO02094264, WO0230358, WO0230357, WO051236976, WO05085212, WO05082865, WO04108717, EP1633729, WO03014153.

15 28. A method as claimed in any preceding claim, wherein the solid tumour or non-haematological tumour is a cancer selected from cancer of the cervix, oesophagus, kidney, brain, breast, ovary, prostate, stomach or pancreas.

20 29. The use of a chemokine receptor CCR4 modulating or inhibiting agent for the treatment or prevention of solid tumours or non-haematological tumours.

30. A use as claimed in claim 29, wherein the agent which modulates or inhibits CCR4 expression or activity is:

25 (i) an antibody which binds to CCR4; optionally an anti-CCR4 antibody as disclosed in any of WO0041724, WO0164754, WO05035582, WO03018635, WO05053741, WO0042074; or

(ii) an antibody which binds to CCR4 ligands CCL17 or CCL22; optionally anti-CCL17 or anti-CCL22 antibodies as disclosed in WO99/15666; or
Ishida, T., *et al* (2004) *Clin Cancer Res* 10:7529-7539.

30 (iii) a CCR4 antagonist; optionally a CCR4 antagonist as disclosed in any of WO04007472, WO05023771, WO02094264, WO0230358, WO0230357,

WO051236976, WO05085212, WO05082865, WO04108717, EP1633729,
WO03014153.

31. A use as claimed in claim 29 or claim 30, wherein the solid tumour or non-

5 haematological tumour is a cancer selected from cancer of the cervix, oesophagus, kidney, brain, breast, ovary, prostate, stomach or pancreas.

32. A kit for obtaining information of predictive or diagnostic character for a cancer

patient from a solid tumour or a non-haematological tumour sample from the patient,

10 wherein the kit comprises:

at least one reagent selected from an antibody reactive with CCR4, an antibody reactive with CCL17, an antibody reactive with CCL22, and an oligonucleotide probe or primer capable of hybridizing with SEQ ID NO:1
15 under stringent conditions; and

indicia directing a user of the kit to apply the reagent to a sample of a solid tumour or a non-haematological tumour from a patient so as to measure the amount and/or activity of one or more of CCR4, CCL17 and CCL22 in the sample.

20

33. A kit as claimed in claim 32, further comprising a reference sample of one or more non-tumour cells and the indicia are instructions and direct the user of the kit to measure the amount and/or level of activity of one or more of CCR4, CCL17 and CCL22 in both the patient sample and the reference sample.

25

34. A kit as claimed in claim 32, wherein the indicia are instructions and include reference values for the with a reference amount and/or level of activity of one or more of CCR4, CCL.

30 35. A method of screening for an anti-cancer agent active against a solid tumour or a non-hematological tumour which expresses chemokine receptor CCR4 comprising the steps of:

(i) providing test cells that express CCR4 and are capable of, or are in the process of exhibiting a biological activity selected from (a)

proliferation, (b) migration, (c) secretion of a protein or a signalling molecule, or (d) cell survival when cultured under specified conditions;

- 5 (ii) exposing the test cells to a candidate agent for a period of time,
- (iii) measuring the biological activity of the test cells, whereby no biological activity or biological activity which is less than the expected activity of such test cells in the absence of candidate agent identifies an anti-cancer agent.

10 36. A method as claimed in claim 35, wherein a control aliquot of test cells is not exposed to the candidate agent and the biological activity of the control cells is measured so that the expected biological activity is determined.

15 37. A method as claimed in claim 35 or claim 36, wherein the biological activity of the test cells and any control cells is induced by the addition of a ligand of the CCR4 receptor, preferably CCL17 and/or CCL22.

20

25

30

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

Panel A: Positivity / Percentage of cells

Stage	n=	+0 (0)	+1 (0-10)	+2 (10-20)	+3 (21-30)	+4 (>30)
Normal	23	13.00% (3/23)	86.96% (20/23)	0	0	0
CIN I	30	3.33% (1/30)	40.00% (12/30)	43.33% (13/30)	10.00% (3/30)	3.33% (1/30)
CIN II	17	5.88% (1/17)	41.18% (7/17)	41.18% (7/17)	5.88% (1/17)	5.88% (1/17)
CIN III	14	0	50.00% (7/14)	42.86% (6/14)	0	7.14% (1/14)
SCC	41	2.44% (2/41)	14.63% (6/41)	41.46% (17/41)	31.71% (13/14)	9.76% (4/41)
RECUR.	15	0	53.33% (8/15)	26.67% (4/15)	13.33% (2/15)	6.67% (1/15)
LN METS	10	0	10.00% (1/10)	30.00% (3/10)	50.00% (5/10)	10.00% (1/10)
ADENOCA	10	10.00% (1/10)	60.00% (6/10)	30.00% (3/10)	0	0

Panel B: Staining intensity

Stage	n=	0 (none)	1(+)	2 (++)	3 (+++)
Normal	23	13.04% (3/23)	52.17% (12/23)	21.73% (5/23)	13.04% (3/23)
CIN I	30	3.33% (1/30)	6.66% (2/30)	50.00% (15/30)	40.00% (12/30)
CIN II	17	5.88% (1/17)	17.65% (3/17)	47.05% (8/17)	29.41% (5/17)
CIN III	14	0	21.43% (3/14)	42.86% (6/14)	35.71% (5/14)
SCC	41	2.43% (1/41)	7.31% (3/41)	34.15% (14/41)	56.10% (23/41)
RECUR.	15	0	13.33% (2/15)	33.33% (5/15)	53.33% (8/15)
LN METS	10	0	0	20.00% (2/10)	80.00% (8/10)
ADENOCA	10	10.00% (1/10)	20.00% (2/10)	50.00% (5/10)	20.00% (2/10)

Figure 9

Panel A: Positivity / Percentage of cells

Stage	n=	+0 (0%)	+1 (<25%)	+2 (26-50%)	+3 (51-75%)	+4 (>76%)
Normal	23	95.65% (22/23)	0	4.34% (1/23)	0	0
CIN I	30	3.33% (1/30)	13.33% (4/30)	16.66% (5/30)	6.66% (2/30)	60.00% (18/30)
CIN II	17	5.88% (1/17)	11.76% (2/17)	5.88% (1/17)	17.75% (3/17)	58.82% (10/17)
CIN III	16	6.25% (1/16)	6.25% (1/16)	12.50% (2/16)	25.00% (4/16)	50.00% (8/16)
SCC	45	4.44% (2/45)	2.22% (2/45)	0	11.11% (5/45)	82.22% (37/45)
RECUR.	15	0	6.67% (1/15)	13.33% (2/15)	0	80.00% (12/15)
LN METS	10	0	10.00% (1/10)	0	20.00% (2/10)	70.00% (7/10)
ADENOCA	10	10.00% (1/10)	10.00% (1/10)	20.00% (2/10)	20.00% (2/10)	40.00% (4/10)

Panel B: Staining intensity

Stage	n=	0 (none)	1(+)	2(++)	3 (+++)
Normal	23	95.65% (22/23)	4.34% (1/20)	0	0
CIN I	30	3.33% (1/30)	16.66% (5/30)	30.00% (9/30)	50.00% (15/30)
CIN II	17	5.88% (1/17)	29.41% (5/17)	35.29% (6/17)	29.41% (5/17)
CIN III	16	6.25% (1/16)	25.00% (4/16)	50.00% (8/16)	18.75% (3/16)
SCC	45	4.44% (2/45)	22.22% (10/45)	37.78 % (17/45)	35.56% (16/45)
RECUR.	15	0	26.66% (4/15)	26.66% (4/15)	46.67% (7/15)
LN METS	10	0	40.00% (4/10)	20.00% (2/10)	40.00% (4/10)
ADENOCA	10	10.00% (1/10)	30.00% (3/10)	30.00% (3/10)	30.00% (3/10)

Figure 10a




Figure 10b




Figure 11




Figure 12




Figure 13

<400> 1	
atgaaccca cgatatacg agataccacc ctgcgtgaaa gcatatacag caattactat	60
ctgtatgaaa gtatccccaa gccttgcacc aaagaaggca tcaaggcatt tggggagctc	120
ttcctgcccc cactgtattc ctgggtttt gtatttggtc tgcttgaaa ttctgtggtg	180
gttctggtcc tgttcaaata caagcggctc aggtccatga ctgatgtgta cctgctcaac	240
cttgcacatct cgatctgct cttcgtgtt tccctccctt tttggggcta ctatgcagca	300
gaccagtggg ttttgggct aggtctgtgc aagatgattt cctggatgta cttggtgggc	360
ttttacagtg gcatattctt tgtcatgctc atgagcattt atagataacct ggcatatgt	420
cacgcggtgt tttccttgag ggcaaggacc ttgacttatg gggcatcac cagttggct	480
acatggtcag tggctgtgtt cgcctccctt cctggcttc tggtcagcac ttgttatact	540
gagcgcaacc atacctactg caaaaccaag tactctctca actccacgac gtggaaaggtt	600
ctcagctccc tggaaatcaa cattctcgga ttgggtatcc ctttagggat catgctgttt	660
tgctactcca tgatcatcag gaccttgcag cattgtaaaa atgagaagaa gaacaaggcg	720
gtgaagatga tctttgcgt ggtggcctc ttccttggt tctggacacc ttacaacata	780
gtgctttcc tagagaccct ggtggagcta gaagtccttc aggactgcac ctttggaaaga	840
tacttggact atgccatcca gcccacagaa actctggctt ttgttcaactg ctgccttaat	900
cccatcatct actttttct gggggagaaa ttgcgtcaagt acatcctaca gctcttcaaa	960
acctgcagg gctttttgt gctctgccaa tactgtggc tcctccaaat ttactctgt	1020
gacaccccca gctcatcttta cacgcgtcc accatggatc atgatcttca tgatgtctg	1080
tag	1083